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Background: Around 60,000 babies are born preterm (prior to 37 weeks’ gestation) each year in the
UK. There is little evidence on the optimal birth mode (vaginal or caesarean section).
Objective: The overall aim of the CASSAVA project was to determine if a trial to define the optimal
mode of preterm birth could be carried out and, if so, determine what sort of trial could be conducted
and how it could best be performed. We aimed to determine the specific groups of preterm women
and babies for whom there are uncertainties about the best planned mode of birth, and if there would
be willingness to recruit to, and participate in, a randomised trial to address some, but not all, of these
uncertainties. This project was conducted in response to a Heath Technology Assessment programme
commissioning call (17/22 ‘Mode of delivery for preterm infants’).
Methods: We conducted clinician and patient surveys (n = 224 and n = 379, respectively) to identify
current practice and opinion, and a consensus survey and Delphi workshop (n = 76 and n= 22 participants,
respectively) to inform the design of a hypothetical clinical trial. The protocol for this clinical trial/
vignette was used in telephone interviews with clinicians (n = 24) and in focus groups with potential
participants (n = 13).
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Results: Planned sample size and data saturation was achieved for all groups except for focus groups
with participants, as this had to be curtailed because of the COVID-19 pandemic and data saturation
was not achieved. There was broad agreement from parents and health-care professionals that a trial
is needed. The clinician survey demonstrated a variety of practice and opinion. The parent survey
suggested that women and their families generally preferred vaginal birth at later gestations and
caesarean section for preterm infants. The interactive workshop and Delphi consensus process
confirmed the need for more evidence (hence the case for a trial) and provided rich information on
what a future trial should entail. It was agreed that any trial should address the areas with most
uncertainty, including the management of women at 26–32 weeks’ gestation, with either spontaneous
preterm labour (cephalic presentation) or where preterm birth was medically indicated. Clear themes
around the challenges inherent in conducting any trial emerged, including the concept of equipoise
itself. Specific issues were as follows: different clinicians and participants would be in equipoise for
each clinical scenario, effective conduct of the trial would require appropriate resources and expertise
within the hospital conducting the trial, potential participants would welcome information on the trial
well before the onset of labour and minority ethnic groups would require tailored approaches.
Conclusion: Given the lack of evidence and the variation of practice and opinion in this area, and
having listened to clinicians and potential participants, we conclude that a trial should be conducted
and the outlined challenges resolved.
Future work: The CASSAVA project could be used to inform the design of a randomised trial and
indicates how such a trial could be carried out. Any future trial would benefit from a pilot with
qualitative input and a study within a trial to inform optimal recruitment.
Limitations: Certainty that a trial could be conducted can be determined only when it is attempted.
Trial registration: Current Controlled Trials ISRCTN12295730.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 25, No. 61. See the NIHR Journals Library website for further project information.
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Around 60,000 babies are born preterm each year in the UK. We do not know what the safestmode of birth is for these babies. Birth options include a vaginal birth or a caesarean section
(which involves an operation for the mother). Normally, the ideal way to find out what clinical options
are best is to carry out a ‘randomised trial’ in which participants are allocated to a particular treatment
group (in this case, vaginal birth or caesarean section) by chance. It is not clear if women who have
their babies preterm would want to take part in such a trial or that the clinicians looking after the
women would be happy to ask them to, as previous trials have failed to recruit sufficient participants.
The purpose of the CASSAVA research project was to find out what people think is the best and safest
method of delivering preterm babies, their views on doing a research trial and what sort of research
trial could be carried out.
We conducted a survey asking clinicians and women their views. We gathered clinicians and women
together to discuss and agree the key questions for a trial to answer. We then developed a protocol
(plan) for a possible trial. Using this trial protocol, we conducted telephone interviews with clinicians,
asking them if they would be willing to be involved and if they would be willing to ask pregnant
women to participate. We also conducted focus groups with women, using a vignette (storyboard)
about a possible trial.
We found that there is a lot of uncertainty about the best way for preterm babies to be born.
Clinicians and women broadly agreed that it would be good to resolve this uncertainty through a trial.
We were able to identify some areas of the greatest uncertainty where clinicians and women would
consider participating in a study. We gained a lot of useful information about how we could best set up
a trial and support clinicians and women to get involved.
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Preterm birth (PTB) (prior to 37 weeks’ gestation) affects 7% of UK livebirths, and is the single largest
cause of neonatal mortality and morbidity. Importantly, although survival rates have increased with
time, rates of disability have remained unchanged. Despite the relatively common nature of PTB,
there is significant uncertainty about which mode of birth (MoB) [vaginal or caesarean section (CS)] is
best. This uncertainty was highlighted in the 2015 National Institute for Health and Care Excellence
guidance on preterm labour and birth, in which clinicians were advised ‘to discuss the risks and
benefits of vaginal and caesarean delivery with women thought to be in preterm labour and to
highlight the potential risks associated with caesarean sections’ (National Institute for Health and
Care Excellence. Preterm Labour and Birth. London: National Institute for Health and Care Excellence;
2015. © NICE 2015 Preterm Labour and Birth. Available from www.nice.org.uk/guidance/ng25.
All rights reserved. Subject to Notice of rights NICE guidance is prepared for the National Health
Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn.
NICE accepts no responsibility for the use of its content in this product/publication).
Despite this advice, the evidence base on risks and benefits is limited largely to observational studies.There
is uncertainty as to whether or not a randomised trial is possible, in part because of established practice.
The research described in this monograph was in response to a Health Technology Assessment-
commissioned call (17/22 ‘Mode of delivery for preterm infants’) to:
. . . establish the scenarios in which there is equipoise in how best to deliver a preterm baby and to define
the most important outstanding question(s) for clinicians and parents in this area that could be addressed
by a future trial. If outstanding questions are identified in this first phase then researchers are asked to
conduct qualitative work with clinicians and potential participants to determine the acceptability of
randomisation in order to inform the feasibility of future research.
Objective
The overall aim of the CASSAVA project was to determine whether and what sort of trial could be
done to define the optimal mode of preterm birth. We planned to find the groups of women and babies
in preterm labour with whom there is clinical uncertainty about the optimal planned mode of birth, and
whether or not women and clinical staff would be willing to participate in a future randomised trial to
address this question. We aimed to determine the specific groups of preterm women and babies where
there are uncertainties about the best planned mode of birth, and where there would be willingness to
recruit to/participate in a randomised trial to address some but not all of these uncertainties.
Methods
We planned a series of clinician and patient surveys and a consensus workshop/Delphi group to inform
the design of a hypothetical clinical trial (HCT). We planned to devise a protocol for the HCT and a
vignette for discussion with potential participants. We planned focus groups (FGs) to talk to potential
participants about the trial and telephone interviews to talk to clinicians. Last, we had planned to
design and cost a future trial.
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Results
We broadly achieved our aims. We conducted clinician and patient surveys and the consensus
workshop, achieving our planned sample size for each. These events were richly informative for the
design of a protocol for a HCT (which we called CASSAVAplus) and a vignette for discussion with
potential participants. We also reached our planned sample size for in-depth interviews with clinicians.
Unfortunately, our FGs with participants had to be curtailed because of the COVID-19 pandemic and
data saturation was not achieved.
The clinician survey demonstrated a variety in practice and opinion. The parent survey suggested
that women and their families generally preferred vaginal birth at later gestations and CS for
preterm infants. The interactive workshop and Delphi consensus process confirmed the need for
more evidence and, hence, the case for a trial. The Delphi consensus process provided rich information
on what sort of trial could be conducted and how it could best be performed. It was agreed that
any trial should address the areas with most uncertainty, including the management of women at
26–32 weeks’ gestation with either spontaneous preterm labour (cephalic presentation) or where
PTB was medically indicated.
Several other clear themes were identified and these are listed below:
l The challenges of the concept of equipoise for both participants and clinicians.
l Not all clinicians and not all potential participants are in equipoise about every clinical situation
(despite the lack of formal evidence).
l There is a need for clinicians to have confidence in trial design, resources, the trial team and their
clinical abilities to deliver both arms of any trial (e.g. performing vaginal breech deliveries).
l Clinicians would value the option of selecting their own inclusion and exclusion criteria (within a
range offered by the trial) that are tailored to their own areas of equipoise.
l There is need for participants to be provided with information about the trial early on in the
process (i.e. before labour).
l There is a need to tailor recruitment approaches for particular participants, including those from
minority ethnic groups.
l Any trial in this area is likely to be ‘challenging’.
Conclusions
Implications for health care
Evidence is lacking on the optimal MoB for the 60,000 babies born preterm in the UK each year. Both
women and clinicians would like more evidence, but are conscious of the challenges inherent in
recruiting to and participating in any trial.
Implications for research
A trial to determine the optimal MoB for women and babies at risk of PTB is urgently needed, but will
be challenging to conduct. The outline and detailed design of CASSAVAplus, which we used to consult
with potential participants and clinicians, provides a template that can be modified with feedback
gained, after further systematic review and with consideration of a likely budget envelope. A study
within a trial could be helpful in determining the most inclusive approach for involving pregnant
women from ethnic minorities at risk of PTB. A pilot within any substantive trial, supported by
qualitative methodology, could inform trial procedures, and an adaptive design might address the
variety in participant characteristics.
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Summary
There is broad agreement from parents and health-care professionals that a trial on the optimal MoB
for preterm babies is needed. We conclude that a trial should be conducted and the challenges
outlined resolved. The CASSAVA project has provided a strong basis on how to move forward and how
such a trial could be carried out.
Trial registration
This trial is registered as ISRCTN12295730.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 61.
See the NIHR Journals Library website for further project information.
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Methods of birth in preterm birth
Preterm birth (PTB) (prior to 37 weeks’ gestation) affects 7% of UK livebirths and is the single largest
cause of neonatal mortality and morbidity. Survival to 1 year of life and rates of disability are inversely
proportional to length of gestation (i.e. babies born at lower gestational ages do worse than those born
at higher gestational ages). Importantly, although survival rates have increased with time, rates of
disability have remained unchanged.1,2
Despite the relatively common nature of PTB, there is significant uncertainty about which mode of
birth (MoB) [vaginal or caesarean section (CS)] is best. Current guidance advises clinicians to discuss
the risks and benefits of vaginal and caesarean birth with women thought to be in preterm labour and
to highlight the potential risks associated with CSs.
Despite this advice, the evidence base on risks and benefits is limited largely to observational
studies. There is uncertainty as to whether or not a randomised trial is possible, in part because
of established practice.
The research described in this monograph was in response to a Health Technology Assessment
commissioned call (17/22 ‘Mode of delivery for preterm infants’) to:
. . . establish the scenarios in which there is equipoise in how best to deliver a preterm baby and to define
the most important outstanding question(s) for clinicians and parents in this area that could be addressed
by a future trial. If outstanding questions are identified in this first phase, then researchers are asked to
conduct qualitative work with clinicians and potential participants to determine the acceptability of
randomisation in order to inform the feasibility of future research.
Uncertainty about the best-planned mode of birth for women in spontaneous preterm labour
The majority of PTBs follow the premature initiation of spontaneous labour. There is clinical uncertainty
about the optimal MoB in this scenario. A minority of women require CS (e.g. those with fulminating
pre-eclampsia), and these women are not the focus of this study. For the remainder of women, there
is significant clinical uncertainty, and some clinicians believe that birth by CS is best because of the
hypothesised reduction in birth trauma and intrapartum hypoxia. Others believe that vaginal birth
confers advantages for the baby (e.g. reducing respiratory morbidity), the mother (e.g. avoiding operative
complications) and the NHS (e.g. costs). There are similar uncertainties about the best mode of planned
PTB. Addressing these clinical uncertainties could significantly improve the health of the public and
patients. Rates of intrapartum stillbirth and neonatal and long-term mortality and morbidity are higher
in the 60,000 preterm babies born in the UK each year than with term babies.
In addition to these clinical uncertainties, there is very little evidence on the best MoB. To the best
of our knowledge, there is only one systematic review3 of randomised trials on this topic. In this
systematic review,3 only four studies (involving only 116 women) were considered to be sufficiently
robust to be able contribute data to the analysis, and the most recent study was conducted 25 year ago.
There were very few data of relevance to the two main (primary) outcomes for the baby considered
in the review [i.e. birth injury to infant and birth asphyxia (as defined by the triallists)]. For the mother,
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there were very few data on the primary outcome of admission to intensive care/major maternal post-
partum complications; however, women in the vaginal birth group had lower rates of puerperal pyrexia
[relative risk (RR) 2.98, 95% confidence interval (CI) 1.18 to 7.53; three trials, n = 89 women] and other
maternal infection (RR 2.63, 95% CI 1.02 to 6.78; three trials, n = 103 women). The authors concluded
that ‘there is not enough evidence to evaluate the use of a policy of planned immediate caesarean birth
for preterm babies. Further studies are needed in this area’.3
The Cochrane systematic review was updated by the Guideline Development Group for the National
Institute for Health and Care Excellence (NICE) Preterm Labour and Birth guideline (2015),4 which found
no new randomised trials. A further update of this search was conducted in November 2017 prior to
submission of the full grant application for this study using the medical subject headings premature
birth AND delivery; obstetric AND randomised trial; premature birth AND caesarean delivery AND
randomised trial; premature birth AND labor AND obstetric AND randomised trial, with publication
date of January 2011–November 2017 (see Appendix 1). Again, we found no new randomised trials
to address the question of the best MoB for women in preterm labour or undergoing planned PTB.
A further scoping search was undertaken in preparation for the Delphi exercise on 18 May 2019 and,
again, no new randomised trials were found. Both of our own searches identified some observational
studies. An initial review of these observational studies shows the extent of the controversy, with
evidence both of worse outcomes5,6 and of better outcomes7,8 in babies delivered by CS than in babies
delivered vaginally, and also evidence of no difference.9 It is plausible that planned birth by CS could
reduce the frequency of either death or disability in preterm babies compared with the control
standard of care of vaginal birth. Indeed, our recent retrospective study of 1575 UK babies born
between 23 and 27 weeks’ gestation found that, after adjusting for confounders, babies born vaginally
had a higher odds (OR 1.61, 95% CI 1.01 to 2.58) of intraventricular haemorrhage (IVH).8 Another
study has shown that neonatal mortality is lower in babies born by CS than in babies born vaginally.10
Conversely, CS is associated with higher NHS costs and greater complications for the mother,11
and there is conflicting evidence of benefit for preterm babies.3,5,6
Importantly, there is uncertainty about the subgroups of women (e.g. those with cephalic presentation
only, those at a particular gestational age and those without any signs of intrauterine growth restriction)
for whom there is equipoise about the appropriate MoB. A brief description of these subgroups of
women follows. First, there may be one or more babies. The Cochrane review12 and the NICE guideline4
focused on singleton pregnancy (i.e. just one baby), and we intended to include discussion about multiple
pregnancy in our research in order not to narrow the question too quickly. Second, the baby (or babies)
may be presenting by the breech or cephalic. (It is assumed that babies with a non-longitudinal lie
would require birth by CS.) Three of the four studies in the Cochrane review12 focused on babies with
breech presentation. There is arguably less controversy about the optimal MoB in women delivering
preterm with breech presentation, as randomised trials of term babies have provided evidence of
the advantages of CS for these babies.13 Indeed, the NICE guideline Preterm Labour and Birth4
acknowledges this and suggests that, for women in preterm labour with breech presentation,
CS should be ‘considered’.4 Last, it is plausible that the risks and benefits of CS and vaginal birth
may be different when comparing women who are in preterm labour with women undergoing
planned PTB. Both subsets of women are included in the commissioning brief and we have
addressed both in our research described here.
Despite the lack of evidence and uncertainty in the national guidance,11 it is not clear whether
clinicians and pregnant women are in equipoise about the best MoB. Acknowledging that published
evidence is only one source of information that clinicians and women use for clinical decision-making,
the purpose of this study was to determine ‘[i]n which groups of women and babies in preterm labour
is there clinical uncertainty about planned mode of birth’.
INTRODUCTION
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Uncertainty about whether or not a trial to compare planned modes of birth is feasible
In addition to the uncertainty about the best-planned MoB, there is uncertainty about whether
or not a trial to compare planned modes of birth is feasible. Clinicians may not wish to randomise
women to CS or vaginal birth because they have firm beliefs about the optimal MoB (despite the
lack of published evidence). Likewise, pregnant women may not wish randomisation for a variety of
reasons, including the experience of friends or family. The uncertainty about whether or not women
and clinicians would accept randomisation has been given prominence by the Cochrane review, which
noted that ‘[f]urther studies are needed in this area [of best method of delivery], but recruitment is
proving difficult’.3 The comment on difficult recruitment arose because all four of the randomised
trials, which provided data for the Cochrane review, closed without having reached their sample size.
However, three14–16 out of four of these studies focused on women with breech presentation for whom
there is less clinical uncertainty (as described above). The most recent of these studies (of breech
presentation) was published over 20 years ago.14 In addition, the rationale for early termination of the
study of singleton babies with cephalic presentation was because of an ‘unacceptably high proportion
(63%) of babies with birthweight > 1500 g’ and not because of poor recruitment. This fourth trial
was published over 30 years ago.17 Therefore, there is little evidence to determine whether or not
recruitment to a randomised trial of MoB is feasible, and much of the available evidence is from
women delivering over 25 years ago.
This project aims to determine which groups of women in preterm labour or with planned PTB would
be willing to randomise to a potential future trial. Randomised trials have been performed to address
optimal MoB for women with breech presentation13 and women with twin pregnancy,18 and these trials
have (arguably) reduced uncertainty. However, there are few randomised trials to compare planned
CS with vaginal birth for women with a singleton pregnancy and cephalic presentation at term.19
Importantly, in a previous study of women with a previous CS at full-term gestation, comparing elective
repeat CS with vaginal birth, the majority of women were allocated by patient preference rather than
randomisation, implying reluctance to randomise or be randomised.20
Rationale for research
Aims
This project, which we called the CASSAVA project, was funded by the National Institute for Health
Research as part of the Health Technology Assessment programme. The overall aim of the project was
to find out the groups of women and babies in preterm labour for whom there is clinical uncertainty
about the optimal planned mode of birth and whether or not women and clinical staff would be willing
to participate in a future randomised trial to address this question. We aimed to determine which of
the four statements below is most accurate and to define any uncertainties:
1. There are no uncertainties about the best-planned MoB for any groups of women or babies
presenting in preterm labour.
2. There are uncertainties about the best-planned MoB for specific subgroups of women (which we
will define) presenting in preterm labour, and in the willingness of clinicians to recruit to, and of
women to participate in, a randomised trial to address these uncertainties.
3. There are uncertainties about the best-planned MoB for specific subgroups of women (which we
will define) presenting in preterm labour, and in the willingness of clinicians to recruit to, and of
women to participate in, a randomised trial to address some, but not all, of these uncertainties.
4. There is uncertainty about the best-planned MoB for specific subgroups of women (which we will
define) presenting in preterm labour, but women and/or clinical staff are not willing to participate in
a randomised trial to address any of these uncertainties.
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Objectives
To achieve our overall aim, our stated objectives were as follows:
l To perform two surveys: one survey with health-care professionals to establish current practice and
opinion in key clinical scenarios of women presenting in preterm labour (e.g. cephalic/breech, previous
CS or not, growth restriction present or not, gestational age of 23–24, 24–28 or 28–36 weeks)
(see Chapter 3) and a second survey with parents to establish current opinion about the best MoB
(see Chapter 4).
l To convene an interactive working group of clinicians to determine what kind of trials still need
to be carried out and what groups of women should be included in these trials. Formal consensus
methodology was used to resolve uncertainties (see Chapter 5).
l To design a randomised trial that addresses the agreed most important clinical uncertainties. In line
with the Health Technology Assessment brief, we anticipated that the ‘control’ in our randomised
trial would be planned vaginal birth and the ‘intervention’ would be planned CS, but this would be
informed by the survey.
l To mock up a short trial protocol (see Chapter 6), together with a rich descriptive vignette of the
trial scenario and participant information sheets, to facilitate the qualitative study described below.
l To perform a qualitative study among clinicians and women to determine remaining key issues and
the acceptability of randomisation (see Chapter 7). We aimed to conduct telephone interviews with
health-care professionals and focus groups (FGs) with women, including those who have had, or
who are at risk of, PTB.
Assuming that there are clinical uncertainties that can be addressed by a trial to which women and
clinicians will support recruitment, we aimed to finalise the design (and approximate costs) of a
randomised trial of CS compared with vaginal birth to determine the optimal MoB of women presenting
in preterm labour.
INTRODUCTION
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Chapter 2 Study design
Study design
To achieve our staged aims, we planned two surveys: one with health-care professionals to establish
current practice and opinion in key clinical scenarios of women presenting in preterm labour
(e.g. cephalic/breech, previous CS or not, growth restriction present or not, gestational age of 23–24,
24–28 or 28–36 weeks) and one with parents to establish current opinion about the best MoB.
These surveys are described in more detail, with results, in Chapters 3 and 4.
Informed by the surveys and by an updated literature review, we then convened an interactive working
group of clinicians to determine what kind of trials still need to be carried out and what groups of
women should be included in these trials. Formal consensus methodology (Delphi) was used to resolve
uncertainties. More detail about this Delphi process and the results are described in Chapter 5.
Next, we designed a randomised trial (CASSAVAplus) (see Chapter 6) that would address the agreed
most important clinical uncertainties. In line with the Health Technology Assessment brief, the ‘control’
in our randomised trial was vaginal birth and the ‘intervention’ was planned CS, and this approach was
validated by the clinician survey. In addition, we generated a rich descriptive vignette of the trial
scenario and participant information sheets to facilitate the qualitative study.
Last, we performed a qualitative study among clinicians and women to determine remaining key
issues and the acceptability of randomisation. We conducted telephone interviews with health-care
professionals, and FGs with women, including those who have had, or who are at risk of, PTB.
More details on the qualitative study and its results are provided in Chapter 7.
Thereafter, we had planned to finalise the design (and approximate costs) of a randomised trial of CS
compared with vaginal birth to determine the optimal MoB of women presenting in preterm labour.
In practice, the COVID-19 pandemic (March 2020) curtailed further project development and so we
have been unable to do this. However, Chapter 8 describes strategies for doing this in the future should
a trial be commissioned or funded.
Ethics approval and research governance
A study protocol was written to include the surveys, the consensus workshops and Delphi process, and
the qualitative interviews and FGs.
The protocol was approved by the London – City & East Research Ethics Committee on 30 April 2019
(reference 18/LO/1616). Local research and development approval was given in Edinburgh on
13 February 2019. Protocol amendments are described in Table 1 and sponsor (University of Edinburgh,
Edinburgh, UK) approval was obtained on 15 October 2018, with approval from the NHS Research
Scotland Permissions Coordinating Centre and the Health Research Authority on 30 October 2018.
The funder approved all versions of the protocol prior to submission to ethics.
Participants
Inclusion criteria
For the survey, we aimed to include consultant obstetricians, neonatologists and midwives working
in hospitals with neonatal intensive care units (as these are the only hospitals that will deliver the
extreme PTBs, which are included in the scenarios). For the patient survey, we included all parents who
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request Classification Reason for change Approved by Categorya
Approval process
complete
1 29 October 2018 Non-substantial Funder requested addition of the REC reference number
(i.e. 18/LO/1616) and that Section 18 – Protocol
Amendments – should state that any amendments
should also be submitted to the funder for authorisation
prior to submission to ethics
Sponsor, HRA/NRS
PCC, REC
C 29 October 2018
2 25 March 2019 Substantial 01 Following the staff pilot survey, we made changes to the
CASSAVA questionnaire for staff
Sponsor, HRA/NRS
PCC, REC
C 25 March 2019
3 30 January 2019 Non-substantial Change of PI for Edinburgh Royal Infirmary from
Professor Jane E Norman to Dr Sarah Stock
Sponsor, NRS PCC B 30 January 2019
4 30 April 2019 Substantial 02 A new invitation to attend the Delphi meeting to be held
in London on 5 July 2019
Sponsor, HRA/NRS
PCC, REC
A 30 April 2019
5 24 October 2019 Substantial 03 New or updated documents:. CASSAVA_
PIS_HCP_V2_17092019. CASSAVA_HCP_Staff_Consent
form _ V2_17092019. CASSAVA_PIS (women)
_V2_17092019. Cassava_Women_Consent
form_V2_17092019. Cassava_Women_OPT-IN_FORM
women)_V2_17092019. HCP invitation email to
interview_V1_03 Sep 19. CASSAVA_OPT_IN_FORM
(HCP)_V1_03092019. CASSAVA Data Information Sheet





































request Classification Reason for change Approved by Categorya
Approval process
complete
6 16 December 2019 Non-substantial One change to the consent form for staff involved in
interviews for the qualitative part of the study. The date
of the CASSAVA data information sheet was incorrectly
noted on the consent form: CASSAVA_HCP_Staff_
Consent form _ V3_18 November 2019. CASSAVA Data
Information Sheet v1.0_07082018
Sponsor, HRA/NRS PCC C 16 December 2019
7 15 January 2020 Non-substantial Typographical correction to the original IRAS form dated
28 August 2018. Name of the hospital site amended
Sponsor, HRA/NRS PCC B 15 January 2019
8 15 April 2020 Non-substantial Owing to the restrictions imposed in relation to the
COVID 19 pandemic, we were unable to arrange for
women to attend FGs in person, as planned. It was,
therefore, proposed that these meetings be held as
virtual FGs in place of face to face interaction. The list of
was follows: CASSAVA_PIS (women)_ V3_15042020;
Cassava_Women_Consent form_ V3_15042020
Sponsor, HRA/NRS PCC C 4 June 2020
HRA, Health Research Authority; IRAS, Integrated Research Application System; NRS PCC, NHS Research Scotland Permissions Coordinating Centre; PI, principal investigator;
REC, Research Ethics Committee.


































































































































































































































































































responded to the advertisement by Tommy’s (London, UK) and Bliss (London, UK), charities involved in
patient support and campaigning for better care for PTB, for responses.
For the consensus workshop and qualitative interviews, we aimed to recruit clinicians (including
obstetricians, anaesthetists, midwives, nurses, neonatologists and midwives) with ≥ 5 years experience
of providing clinical care to women at risk of preterm labour or preterm infants.
For the consensus workshops and Delphi process, we included women and their partners who fulfilled
the following criteria:
l aged > 16 years
l willing to consent
l women with previous experience of preterm labour or delivery
l women at risk of future preterm labour or delivery.
For the FGs, we recruited women who fulfilled the following criteria:
l aged > 16 years
l willing to consent.
Exclusion criteria
For the survey, we excluded clinicians working in units that did not have neonatal intensive care
facilities. Women and their partners who experienced adverse events as a result of the issues above
(e.g. neonatal death, stillbirth) were not actively excluded from the consensus workshops or FGs,
but we were mindful of the need to manage this sensitively. The members of the research team have
significant experience of conducting mixed-methods research with parents who have experienced
adverse events, including perinatal death.
Recruitment procedure
We aimed to recruit health-care professionals for the survey through our professional networks of
contacts. We focused on clinicians participating in existing PTB intervention studies currently led by
co-applicants involved in this study. We invited participation through the NHS Preterm Birth Network
and Royal College of Obstetricians and Gynaecologists (RCOG) Preterm Birth Clinical Study Group
(London, UK). In addition, we planned to advertise the survey through the Royal College of Obstetricians
and Gynaecologists, the Royal College of Midwives (London, UK), the British Maternal and Fetal Medicine
Society (London, UK), the British Association of Perinatal Medicine (London, UK) and the Neonatal Society
(Edinburgh, UK). At the end of the survey, we planned to ask participating clinicians if they would be willing
to be contacted to take part in an interview in the qualitative phase of the study.
We aimed to recruit patient participants for the survey through our charity partners Tommy’s and Bliss
on an opt-in basis.
Those who agreed to further contact through the survey were invited by e-mail to participate in the
consensus working group and Delphi survey.
Clinicians who indicated at the end of the survey that they would be willing to be contacted to take
part in an interview were sampled purposefully for an in-depth interview according to their survey
responses (ensuring a mix of those in favour of CS and vaginal birth, respectively). Some additional
‘snowball sampling’ was also undertaken to achieve representation of the different kinds of clinical
staff who would be involved in recruiting into the proposed trial (e.g. obstetricians, neonatologists,
midwives and research midwives) from different areas.
STUDY DESIGN
NIHR Journals Library www.journalslibrary.nihr.ac.uk
8
Women were identified for recruitment into the FGs by social media posts on Facebook (URL: www.
facebook.com; Facebook, Inc., Menlo Park, CA, USA), Twitter (URL: www.twitter.com; Twitter, Inc.,
San Francisco, CA, USA) and Instagram (URL: www.instagram.com; Facebook, Inc., Menlo Park, CA, USA),
and by charity partner connections with local community groups.
Informed consent
All participants were given an information sheet about the study. Completion of the survey was
assumed to indicate consent. Those women/clinicians participating in the Delphi survey, FGs and
interviews were asked to provide written consent before they did so.
Outcome measures
Outcome measures were participant opinions, as derived from the surveys, consensus workshops,
Delphi, interviews or FGs.
Sample size
Our planned sample sizes were as follows: 200 participants for the clinician survey, 200 participants
for the patient survey, 40 participants for the interactive working group and Delphi survey, between
30 and 60 participants for the FGs with women and 25 participants for the interviews with clinicians.
No formal sample size calculations were made.
Statistical analyses
Survey data
We used a five-point Likert scale and analysed it with appropriate non-parametric and parametric
tests. When > 85% of clinicians responding to the survey agreed on an answer to a clinical scenario,
we designated the scenario as having good agreement and being accepted in clinical practice. When
< 50% of clinicians agreed on an answer, we assumed that there was significant clinical uncertainty.
When 50–70% of clinicians agreed, we designated the scenario as having moderate clinical uncertainty.
When 70–85% of clinicians agreed, we designated the scenario as having some clinical uncertainty.
Interactive working group/Delphi survey
Data analysis involved graphical summation of the scores indicating the whole groups’ and individual
participant groups’ responses using ‘DelphiManager’ software [www.liverpool.ac.uk/population-health/
research/groups/comet-initiative/software/ (accessed October 2021)]. Participants were asked to score
each scenario using the GRADE (Grading of Recommendations Assessment, Development and Evaluation)
scale for Delphi processes [accessed online: www.gradeworkinggroup.org (accessed October 2021)].
Participants were asked ‘[h]ow important is to include the following scenarios in a randomised trial of
mode of delivery (caesarean/vaginal) for a preterm baby?’A prespecified scale and criteria21 were used for
dropping and retaining items in the longlist created from the survey. Scenarios with > 70% of participants
scoring 7–10 and scenarios with < 30% of participants scoring 1–3 were included in subsequent rounds.
Qualitative research
Data analysis was undertaken by highly experienced qualitative researchers, with input from other
members of the co-investigator team. Individual interviews were read through repeatedly and
cross-compared to identify issues and experiences that cut across different accounts.22 A similar
approach was used for the FGs discussions, with particular attention being paid to differences and
similarities in the perspectives and views of women belonging to different cultural and religious groups,
and to those with prior experience of CS and vaginal birth. In line with recommendations,23–25 careful
attention was also paid in the analysis to group interactions, including use of humour, as participants’
(different) assumptions can be revealed through the ways they challenge, question and support one
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another in the context of a group discussion.23 Team members undertook separate analyses and wrote
independent reports before meeting to discuss their interpretation of the data and reach agreement
on key findings and themes, which were then used to inform development of a coding frame. Coded
data sets were subjected to further analyses to allow more nuanced interpretations of the data to be
developed and to identify illustrative quotations. NVivo software (version 11; QSR International,
Warrington, UK) was used to support data coding and retrieval.
Study oversight
A Study Steering Committee was appointed to provide oversight for the study and the members of this
committee are listed in the Acknowledgements.
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Chapter 3 The clinician survey
Introduction
This chapter describes a survey with clinicians to establish current practices regarding MoB (offering
women planned CS or labour with the intention of achieving vaginal birth) and opinions in key clinical
scenarios of women presenting at risk of PTB (e.g. cephalic/breech, previous CS or not, indicated birth for
pre-eclampsia or not, twin pregnancy or not and 23, 26 or 32 weeks’ gestation). The results were used to
inform the subsequent interactive consensus workshop and to provide context to the Delphi exercise.
Methods
We performed a survey of clinicians regarding current practices and opinions, offering examples of key
clinical scenarios of women presenting in preterm labour or undergoing planned PTB. The purpose of this
survey was to determine the opinions of clinicians (i.e. obstetricians, neonatologists, anaesthetists and
midwives working in units with neonatal intensive care facilities) on the optimal MoB in different scenarios.
Prior to designing the survey, we consulted expert opinion at a multidisciplinary conference (the
European Spontaneous Preterm Birth Conference, Edinburgh, 16–18 May 2018; ≈ 150 clinicians
responded to the survey) to identify scenarios for which there appeared to be most clinical uncertainty.
Informed by these discussions, the survey was designed focusing on five scenarios:
1. A woman with a singleton pregnancy with established preterm labour.
2. A woman with experience of a previous caesarean birth and in established preterm labour.
3. A woman with PTB indicated by worsening pre-eclampsia (not in labour).
4. A woman with PTB indicated by fetal growth restriction (not in labour).
5. A woman with twins with established preterm labour.
In each scenario, the clinicians were asked to give their opinion on MoB at different gestational ages
(i.e. 23, 26 and 32 weeks’ gestation) and different presentations of baby (i.e. cephalic, flexed breech
and footling breech). In each case, clinicians were asked to give their opinion on MoB on a scale from
1 to 7, with 1 being ‘very likely to recommend CS’, 7 being ‘very likely to recommend vaginal delivery’
and 4 indicating ‘equipoise’. There was also an option to indicate that ‘I am uncertain as it is not within
my clinical expertise’.
The survey was piloted with 20 clinicians, five of whom repeated the questionnaire 2 weeks later.
There was acceptable agreement with responses (75–92%). The wording of questions was modified
for clarity in response to feedback.
The questionnaire (see Report Supplementary Material 1) was designed and administered through
Jisc online surveys (URL: www.onlinesurveys.ac.uk; formerly Bristol Online Surveys), with options
presented as ordinal rating scales. A free-text box for further communication was included at the end
of the questionnaire. A request for demographic information of the respondent (including clinical
specialty and experience) was included at the end of the survey, along with an option to provide
contact details and consent for future contact for interviews and FGs.
The survey was distributed through our professional networks of contacts (including the NHS Preterm Birth
Network and RCOG Preterm Birth Clinical Study Group), advertised at meetings (e.g. the British Maternal and
Fetal Medicine Society annual meeting, Edinburgh, 28 and 29March 2019) and promoted on social media.
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We acknowledge, a priori, that when surveys are distributed through external organisations it is
difficult to determine the proportion of people completing the survey. However, we aimed for
completion from around 200 individuals and for representation from different groups of clinicians
(e.g. obstetricians, neonatologists, anaesthetists and midwives). This large and diverse sample aimed to
overcome any potential bias due to clustering of responses from any particular professional group.
Results were exported in a comma-separated values (CSV) file for analysis. To visualise variation in
practice and clinical uncertainty, categories 1 and 2 were collapsed into ‘favours CS’, categories 3–5
were collapsed into ‘uncertain’ and categories 6 and 7 were collapsed into ‘favours vaginal birth’.
Results are presented as percentages of clinicians surveyed. When < 50% of clinicians surveyed
favoured one MoB (either CS or vaginal birth), then we categorised the scenario as an area of high
variation in opinion. When 50–66% of clinicians favoured one MoB, then we classified the scenario as
an area with considerable variation in practice. When > 66% of clinicians favoured one MoB, then we
classified the scenario as an area with little variation in practice.
Results
We received 224 responses from clinicians working at 72 different UK hospitals and two European
hospitals. Details of specialty and experience are included in Table 2.
The results for each scenario are presented in Figures 1–5 and raw data are included in Report
Supplementary Material 2.
TABLE 2 Details of clinicians participating in questionnaire






Neonatal nursing 13 (5.8)
Other (e.g. radiography) 1 (0.2)
Level of experience
Consultant for ≥ 5 years 85 (37.9)
Consultant for < 5 years 34 (15.2)
Specialty doctor 5 (2.2)
Midwife/neonatal nurse for ≥ 5 years 58 (25.9)
Midwife/neonatal nurse for < 5 years 14 (6.3)
Subspecialty trainee 5 (2.2)
Specialty trainee 4–5 8 (3.6)
Other (e.g. radiographer) 1 (0.2)
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Summary of findings for scenarios 1–5
The percentages of clinicians who favoured CS (scores 1 and 2), vaginal birth (scores 6 and 7) or who
were uncertain (scores 3–5) on the clinician survey in scenarios relating to a woman with a singleton
pregnancy in spontaneous labour are shown in Figure 1. Between 10% and 14% (i.e. between 23 and 31)
of the 224 respondents did not feel that the questions on cephalic presentation were in their expertise,
17–18% (i.e. 39 to 41) of respondents did not feel that the questions on flexed breech presentation were
in their expertise and 17–20% (i.e. 39 to 45) of respondents did not feel that the questions on footling
breech presentation were in their expertise.
The percentages of clinicians who favoured CS (scores 1 and 2), vaginal birth (scores 6 and 7) or who
were uncertain (scores 3–5) on the clinician survey in scenarios relating to a woman with a singleton
pregnancy with previous CS in spontaneous labour are shown in Figure 2. Between 12% and 13%
(i.e. between 27 and 30) of the 224 respondents did not feel that the questions on cephalic presentation
were in their expertise, 18–19% (i.e. 40 to 42) of respondents did not feel that the questions on flexed
breech presentation were in their expertise and 17–20% (i.e. 38 to 45) of respondents did not feel that
the questions on footling breech presentation were in their expertise.
Cephalic 23 weeks’ gestation
Cephalic 26 weeks’ gestation
Cephalic 32 weeks’ gestation
Flexed breech 23 weeks’ gestation
Flexed breech 26 weeks’ gestation
Flexed breech 32 weeks’ gestation
Footling breech 23 weeks’ gestation
Footling breech 26 weeks’ gestation
Footling breech 32 weeks’ gestation





FIGURE 1 Summary of clinician findings for scenario 1.
Cephalic 23 weeks’ gestation
Cephalic 26 weeks’ gestation
Cephalic 32 weeks’ gestation
Flexed breech 23 weeks’ gestation
Flexed breech 26 weeks’ gestation
Flexed breech 32 weeks’ gestation
Footling breech 23 weeks’ gestation
Footling breech 26 weeks’ gestation
Footling breech 32 weeks’ gestation





FIGURE 2 Summary of clinician findings for scenario 2.
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The percentage of clinicians who favoured CS (scores 1 and 2), induction of labour aiming for vaginal
birth (scores 6 and 7) or who were uncertain (scores 3–5) on the clinician survey in scenarios relating
to a woman with a singleton pregnancy with pre-eclampsia are shown in Figure 3. Between 18% and 24%
(i.e. between 41 and 54) of the 224 respondents did not feel that the question on cephalic presentation
was in their expertise, 20–25% (i.e. 45 to 55) of respondents did not feel that the question on flexed
breech presentation was in their expertise and 19–25% (i.e. 43 to 56) of respondents did not feel that
the question on footling breech presentation was in their expertise.
The percentage of clinicians who favoured CS (scores 1 and 2), induction of labour aiming for vaginal
birth (scores 6 and 7) or who were uncertain (scores 3–5) on the clinician survey in scenarios relating
to a woman with a singleton pregnancy with fetal growth restriction are shown in Figure 4. Between
18% and 22% (i.e. between 40 and 49) of the 224 respondents did not feel that the question on
cephalic presentation was in their expertise, 1–24% (i.e. 40 to 54) of respondents did not feel that the
question on flexed breech presentation was in their expertise and 17–23% (i.e. 38 to 51) of respondents
did not feel that the question on footling breech presentation was in their expertise.
Cephalic 23 weeks’ gestation
Cephalic 26 weeks’ gestation
Cephalic 32 weeks’ gestation
Flexed breech 23 weeks’ gestation
Flexed breech 26 weeks’ gestation
Flexed breech 32 weeks’ gestation
Footling breech 23 weeks’ gestation
Footling breech 26 weeks’ gestation
Footling breech 32 weeks’ gestation





FIGURE 3 Summary of clinician findings for scenario 3.
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Flexed breech 26 weeks’ gestation
Flexed breech 32 weeks’ gestation
Footling breech 23 weeks’ gestation
Footling breech 26 weeks’ gestation
Footling breech 32 weeks’ gestation





FIGURE 4 Summary of clinician findings for scenario 4.
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The percentage of clinicians who favoured CS (scores 1 and 2), vaginal birth (scores 6 and 7) or who
were uncertain (scores 3–5) on the clinician survey in scenarios relating to a woman with twin pregnancy
in spontaneous labour are shown in Figure 5. Between 16% and 18% (i.e. between 36 and 40) of the
224 respondents did not feel that the question on cephalic presentation was in their expertise, 20–21%
(i.e. 45 to 47) of respondents did not feel that the question on flexed breech presentation was in their
expertise and 19–22% (i.e. 42 to 50) of respondents did not feel that the question on footling breech
presentation was in their expertise.
Cephalic presentation preterm infant
There was clear consensus for a recommendation of vaginal birth for women in spontaneous preterm
labour with a cephalic presentation baby at all gestations assessed (23, 26 and 32 weeks), even with a
previous CS or with twins (first twin cephalic) (see Figures 2 and 5). In the scenario of an indicated PTB
for pre-eclampsia (see Figure 3) there was less agreement with no consensus at any gestation examined.
If the scenario of indicated PTB for fetal growth restriction and a cephalic baby (see Figure 4) there was
no consensus on MoB at 23 weeks; but some preference for birth by CS at 26 and 32 weeks.
Flexed breech presentation preterm infant
There was no consensus on recommendations for MoB for women with singleton babies in spontaneous
preterm labour with flexed breech infants at 26 and 32 weeks’ gestation (with or without previous CS)
(see Figures 1 and 2). At 23 weeks’ gestation, there was still considerable variation in practice, but vaginal
birth was the more common recommendation (see Figures 1 and 2). In women requiring an indicated
PTB for pre-eclampsia or fetal growth restriction there was no consensus on MoB for babies at
23 weeks’ gestation. However, at 26 weeks’ gestation, there was a slight preference for CS and at
32 weeks’ gestation there was a clear consensus for recommending CS in these scenarios (see Figure 4).
For women with twins in spontaneous preterm labour and first twin flexed breech there was variation,
but more clinicians would recommend vaginal birth than CS at 23 weeks’ gestation. At 26 weeks’
gestation, there was no clear consensus. Last, at 32 weeks’ gestation, more clinicians would recommend
CS than vaginal birth (see Figure 5).
Footling breech presentation preterm infant
The majority of clinicians would recommend vaginal birth for women with a baby with footling breech
presentation in spontaneous preterm labour at 32 weeks’ gestation (regardless of whether or not there
was a previous CS and whether or not there was a twin pregnancy, with the first twin presenting in
Cephalic 23 weeks’ gestation
Cephalic 26 weeks’ gestation
Cephalic 32 weeks’ gestation
Flexed breech 23 weeks’ gestation
Flexed breech 26 weeks’ gestation
Flexed breech 32 weeks’ gestation
Footling breech 23 weeks’ gestation
Footling breech 26 weeks’ gestation
Footling breech 32 weeks’ gestation





FIGURE 5 Summary of clinician findings for scenario 5.
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footling breech). At 23 and 26 weeks’ gestation, there was no clear consensus in women with singleton
pregnancies and no previous CS. In women who had a previous CS, more clinicians would favour
vaginal birth at 23 weeks’ gestation and more clinicians would favour CS at 26 weeks’ gestation.
In women with twins in spontaneous labour at 23 weeks’ gestation, there was no clear consensus,
but at 26 weeks’ gestation more clinicians favoured CS (see Figure 5).
For women requiring indicated PTB for pre-eclampsia or fetal growth restriction with footling breech
presentation, there was no consensus on MoB for babies at 23 weeks’ gestation; however, by 32 weeks’
gestation, there was a clear consensus for recommending CS in both these scenarios. In women with fetal
growth restriction, there was also clear preference for birth by CS at 26 weeks’ gestation (see Figure 4).
In women with pre-eclampsia, there was more variation, but more clinicians preferred CS than vaginal
birth (see Figure 3).
Box 1 summarises the findings on current opinion.
BOX 1 Summary of variation in current clinical opinion
Little variation in opinion: clinicians clearly favour vaginal birth
Singleton with spontaneous labour at 23 weeks’ gestation with cephalic presentation.
Singleton with spontaneous labour at 26 weeks’ gestation with cephalic presentation.
Singleton with spontaneous labour at 32 weeks’ gestation with cephalic presentation.
Singleton with spontaneous labour at 23 weeks’ gestation with flexed breech presentation.
Singleton with spontaneous labour and previous CS at 23 weeks’ gestation with cephalic presentation.
Singleton with spontaneous labour and previous CS at 26 weeks’ gestation with cephalic presentation.
Singleton with spontaneous labour and previous CS at 32 weeks’ gestation with cephalic presentation.
Twins at 23 weeks’ gestation with cephalic first twin presentation.
Twins at 26 weeks’ gestation with cephalic first twin presentation.
Twins at 32 weeks’ gestation with cephalic first twin presentation.
Little variation in opinion: clinicians clearly favour CS
Singleton with spontaneous labour at 32 weeks’ gestation with footling breech presentation.
Singleton with spontaneous labour and previous CS at 32 weeks’ gestation with footling breech
presentation.
Singleton with pre-eclampsia at 32 weeks’ gestation with flexed breech presentation.
Singleton with pre-eclampsia at 32 weeks’ gestation with footling breech presentation.
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Singleton with fetal growth restriction at 32 weeks’ gestation with flexed breech presentation.
Singleton with fetal growth restriction at 26 weeks’ gestation with footling breech presentation.
Singleton with fetal growth restriction at 32 weeks’ gestation with footling breech presentation.
Twins at 32 weeks’ gestation with footling breech first twin presentation.
Considerable variation in opinion: clinicians slightly favour vaginal birth
Singleton with spontaneous labour at 23 weeks’ gestation with flexed breech presentation.
Singleton with spontaneous labour and previous CS at 23 weeks’ gestation with flexed breech presentation.
Singleton with spontaneous labour and previous CS at 23 weeks’ gestation with footling breech
presentation.
Twins at 23 weeks’ gestation with flexed breech first twin presentation.
Considerable variation in opinion: clinicians slightly favour CS
Singleton with spontaneous labour and previous CS at 26 weeks’ gestation with footling breech
presentation.
Singleton with pre-eclampsia at 26 weeks’ gestation with flexed breech presentation.
Singleton with pre-eclampsia at 26 weeks’ gestation with footling breech presentation.
Singleton with fetal growth restriction at 26 weeks’ gestation with cephalic presentation.
Singleton with fetal growth restriction at 32 weeks’ gestation with cephalic presentation.
Singleton with fetal growth restriction at 26 weeks’ gestation with flexed breech presentation.
Twins at 32 weeks’ gestation with flexed breech first twin presentation.
Twins at 26 weeks’ gestation with footling breech first twin presentation.
High variation in opinion: no consensus among clinicians surveyed
Singleton with spontaneous labour at 26 weeks’ gestation with flexed breech presentation.
Singleton with spontaneous labour at 32 weeks’ gestation with flexed breech presentation.
Singleton with spontaneous labour at 23 weeks’ gestation with footling breech presentation.
Singleton with spontaneous labour at 26 weeks’ gestation with footling breech presentation.
BOX 1 Summary of variation in current clinical opinion (continued)
DOI: 10.3310/hta25610 Health Technology Assessment 2021 Vol. 25 No. 61
Copyright © 2021 Norman et al. This work was produced by Norman et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
17
The responses to the question ‘is there a lower limit of gestation before which you would not offer/
recommend caesarean section?’ are shown in Table 3. Fifty-four per cent (122/224) of clinicians responded
that they did have a lower limit, with the median gestation being 24 weeks (range 21–35 weeks).
Thirty-two per cent (71/224) of clinicians had no set lower limit and 14% (31/224) felt that this was
outside their expertise.
Singleton with spontaneous labour and previous CS at 26 weeks’ gestation with flexed breech presentation.
Singleton with spontaneous labour and previous CS at 32 weeks’ gestation with flexed breech presentation.
Singleton with pre-eclampsia at 23 weeks’ gestation with cephalic presentation.
Singleton with pre-eclampsia at 26 weeks’ gestation with cephalic presentation.
Singleton with pre-eclampsia at 32 weeks’ gestation with cephalic presentation.
Singleton with pre-eclampsia at 23 weeks’ gestation with flexed breech presentation.
Singleton with pre-eclampsia at 23 weeks’ gestation with footling breech presentation.
Singleton with fetal growth restriction at 23 weeks’ gestation with cephalic presentation.
Singleton with fetal growth restriction at 23 weeks’ gestation with flexed breech presentation.
Singleton with fetal growth restriction at 23 weeks’ gestation with footling breech presentation.
Twins at 26 weeks’ gestation with flexed breech first twin presentation.
Twins at 23 weeks’ gestation with footling breech first twin presentation.
TABLE 3 Lower limit of gestation at which clinicians would consider performing a CS










No lower limit 71 (32)
Outside expertise 31 (14)
BOX 1 Summary of variation in current clinical opinion (continued)
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Discussion
These findings show that there is considerable variation in UK practice regarding MoB for the preterm
infant. However, the findings indicate that in later preterm babies (i.e. 32 weeks’ gestation or more)
with malpresentation and/or indicated PTB, there is clear consensus for birth by CS and, therefore,
focusing exclusively on these women and infants in a randomised controlled trial (RCT) may result in
low recruitment. Similarly, at the extreme preterm gestation of 23 weeks, vaginal birth was generally
strongly favoured. The survey suggests most variation in MoB of preterm babies in (1) spontaneous
labour with breech presentation between 23 and 32 weeks’ gestation and (2) indicated PTBs (in women
not already in preterm labour) with cephalic presentation. These scenarios informed discussions at the
interactive consensus workshop and subsequent protocol design.
The survey was aimed to provide context for the subsequent interactive consensus workshop and
identify areas where clinical uncertainty was likely. The strengths of the survey were that we surveyed
a variety of clinicians from around the UK and that we piloted the survey. Weaknesses are that,
although we did check the consistency of responses with a small number of participants (n = 5), there
was no formal validation of the survey. Around one-fifth of participants did not feel qualified to
respond to different scenarios. However, this information was useful to inform the range of clinician
specialties and experience to include in the subsequent qualitative work.
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Chapter 4 The public opinion survey
Introduction
This chapter describes a survey with the public to determine their opinions and preferences on MoB
for preterm babies. We provided key clinical scenarios of women presenting in preterm labour or
undergoing planned PTB and asked patients/the public to indicate their preferred option of vaginal
birth or CS. The results were used to inform the subsequent interactive consensus workshop and
provide context to the Delphi exercise.
Methods
A survey was designed and placed on Jisc online surveys, which is an online survey tool designed for
academic research, education and public sector organisations. A website was set up for the survey
and the link distributed, as described below. The survey was designed to be able to be completed on a
smart phone or tablet computer, as well as on a laptop or desktop computer. If people did not have
computer access, we offered to send a paper questionnaire.
Survey design
The survey asked for basic demographic information (i.e. gender, whether or not the individual had
children and whether or not they had experienced PTB). Three clinical scenarios were presented
(Table 4). The first clinical scenario was presented for each of the gestations of 23, 26 and 32 weeks.
The remaining two scenarios focused on 28 weeks’ gestation only. Respondents were asked to indicate
a single option for each scenario and each gestation on a five-point scale as follows:
1. strongly prefer vaginal delivery
2. moderately prefer vaginal delivery
3. no preference for either method of delivery
4. moderately prefer CS
5. strongly prefer CS.
TABLE 4 Clinical scenarios described in the survey
Scenario number Description of scenario
1 Please describe your preferences for the method of delivery if the doctor tells you that a
vaginal delivery and a CS are equally safe for you and the baby. (Tick one option for each of
the gestations of 23, 26 and 32 weeks)
2 Please describe your preference for the method of delivery if the doctor tells you that a
vaginal delivery is safer for you, and that both CS and vaginal delivery are safe for the baby.
You are 28 weeks pregnant
3 Please describe your preferences for method of delivery if the doctor tells you that CS and
vaginal delivery are equally safe for you and that a CS is safer for this baby, but might make
a future pregnancy and birth more risky for you and your baby. You are 28 weeks pregnant
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In addition to this ‘tick-box’ question, participants were also asked to provide free-text comments in
response to a question ‘[p]lease tell us what else you think the NHS should take into account in deciding
whether to recommend a vaginal delivery or a caesarean section in women who are in labour before
37 weeks of pregnancy’.
Survey distribution
The survey was distributed through our charity partners Bliss and Tommy’s in late 2018. The following text
was used to advertise the survey. A link to the survey was sent out by each charity, as described below.
Tommy’s advertised the survey on their Facebook page on 20 November 2018. A screenshot of the
post is given in Report Supplementary Material 3:
Can you help @EdinburghUni? They’re looking for parents with experience of #prematurebirth to fill in a
survey to help them understand the safest way for early babies to be born. To take part in the CASSAVA
study or to find out more, go to bit.ly/2S21ICO.
Reproduced with permission from Shona Low
The Tommy’s centre in Edinburgh advertised the survey on their Facebook page on 13 November 2018.
A screenshot is given in Report Supplementary Material 3:
We would like to tell you about the CASSAVA study. This study is looking at babies and women who are
in premature labour and for whom it is not known which way is the best for them to give birth: whether
it is better (safer) by caesarean section (CS) or better (safer) to try and have a vaginal delivery. The first
part of this research is to find out where clinicians and women feel that more research on this topic is
needed – follow the link to the surveys to help us find out! We would really appreciate your time in
filling out the survey appropriate for you. https://edinburgh.onlinesurveys.ac.uk/pilot-cassava-public- . . .
(Public Survey). There is also plenty more information on the CASSAVA website www.ed.ac.uk/centre-
reproductive-health/cassava Thank you. The Tommy’s team.
Reproduced with permission from Shona Low
Bliss advertised on Facebook, Twitter and Instagram on 7 December 2018. A screenshot of the post is
given in Report Supplementary Material 3:
The University of Edinburgh are researching the best way to manage the birth of women presenting in
preterm labour. They are inviting parents to participate in an online survey to ask their opinions on the
best mode of delivery for preterm labour. You can complete the study at https://edinburgh.onlinesurveys.
ac.uk/pilot-cassava-public- . . . If you are interested in learning more about the project you can visit their
website at www.ed.ac.uk/centre-reproductive-health/cassava.
Reproduced with permission from Caroline Lee-Davey
By 9 December 2018, 72 people had responded to the survey. Following the Bliss posting, we had 307
further responses. The total number of responders was 379.
The survey closed on 9 January 2019.
Consent
An information sheet was provided to participants before completion of the survey. Those participants who
wished to proceed were given access to the survey database. All responders to both the clinician and
public surveys were invited to participate in the Delphi questionnaire process (two rounds) by accessing
https://delphimanager.liv.ac.uk/Cassava/Delphi, which was active from 1 November 2018 to 9 January
2019 (see Report Supplementary Material 4). All participants who completed both rounds were invited to
the consensus meeting in London (held on 5 July 2019).
THE PUBLIC OPINION SURVEY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
22
Results
The summary output from public opinion survey is shown in Report Supplementary Material 5.
A total of 379 people completed the survey, of whom over 95% were female with children and having
experienced a PTB. All surveys were completed electronically and there were no requests for
completion on paper.
When offered the option of a particular mode of birth, in the scenario with the pregnancy being at
23 or 26 weeks’ gestation, there were strong preferences for vaginal birth (> 40%) and also strong
preferences for caesarean birth (> 20%) (Figures 6 and 7). The other options (i.e. moderate or no
preferences) were recorded by < 20% of respondents.
For women at 28 and 32 weeks’ gestation, again, there were high proportions of participants with
strong preferences for vaginal birth (> 49%) (Figures 8 and 9). Smaller numbers of participants strongly
preferred CS at 28 and 32 weeks’ gestation than at earlier gestations (18% at 28 weeks’ gestation and
11% at 32 weeks’ gestation).
1 Strongly prefer vaginal
delivery
2 Moderately prefer vaginal
delivery
4 Moderately prefer CS
5 Strongly prefer CS







FIGURE 6 Method of birth preferences at 23 weeks’ gestation if each (i.e. vaginal birth and CS) are equally safe for
mother and baby.
1 Strongly prefer vaginal
delivery
2 Moderately prefer vaginal
delivery
4 Moderately prefer CS
5 Strongly prefer CS







FIGURE 7 Method of birth preferences at 26 weeks’ gestation if each (i.e. vaginal birth and CS) are equally safe for
mother and baby.
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Taken together, these data suggest that individual women have strong preferences for either vaginal
birth or CS. Vaginal birth is the most frequent ‘preference’ and becomes more frequent with later
gestations (most common at 32 weeks’ gestation). However, a strong preference for CS is most
commonly expressed at earlier gestations [most common at 23 weeks’ gestation (26% of women)].
When faced with the scenario that both options are equally safe for the baby and vaginal delivery is
safest for mother, there was a strong preference for vaginal delivery (61%) (Figure 10), although 9% of
participants still strongly preferred CS.
1 Strongly prefer vaginal
delivery
2 Moderately prefer vaginal
delivery
4 Moderately prefer CS
5 Strongly prefer CS







FIGURE 8 Method of birth preferences at 28 weeks’ gestation if each (i.e. vaginal birth and CS) are equally safe for
mother and baby.
1 Strongly prefer vaginal
delivery
2 Moderately prefer vaginal
delivery
4 Moderately prefer CS
5 Strongly prefer CS







FIGURE 9 Method of birth preferences at 32 weeks’ gestation if each (i.e. vaginal birth and CS) are equally safe for
mother and baby.
1 Strongly prefer vaginal
delivery
2 Moderately prefer vaginal
delivery
4 Moderately prefer CS
5 Strongly prefer CS







FIGURE 10 Method of birth preferences at 28 weeks’ gestation when vaginal delivery is safer for mother and both
vaginal delivery and CS are equally safe for the baby.
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When faced with the scenario that CS is safer for the baby of the index pregnancy, but both CS and
vaginal delivery are equally safe for the mother, then 52% of participants report a strong preference
for CS and 27% of participants moderately prefer CS (Figure 11). These preferences were described,
despite it being acknowledged that CS might make future pregnancies riskier for both mother and baby.
Free-text comments are shown in Report Supplementary Material 5.
Key issues mentioned in the free-text comments (in order of frequency) were safety for baby,
safety for the mother, recovery times and choice. Presentation of information was also clearly
important for respondents.
Discussion
Use of charity partners to access patients and members of the public rapidly generated a large number
of responses. Although it is likely that this approach has preferentially selected those who have an
interest in this topic, and who have previously engaged with charities focused on this topic, we believe
that this approach is likely to be generalisable to the population. It is possible that responses are
influenced by people’s own experiences of birth. Importantly, a large majority of respondents had
experienced PTB. Although we were able to collect basic demographic information, this did not include
information on ethnicity or social exclusion. It is likely that those with limited English, and possibly
those from lower socioeconomic groups, are poorly represented in our sample.
Men and women who have not previously experienced PTB were also poorly represented in our sample.
Although the decision about MoB is formally made by the pregnant woman, partners, friends and
families are influential in women’s decision-making. The demographics of our survey prevents us from
knowing whether or not male partners might come to different conclusions and, therefore, alter decision-
making in practice.
Many women faced with the decision about how their preterm baby should be born will not have
experienced a previous PTB. Including more women for whom this would be a novel experience would
have been helpful; however, these women are less likely to be interested in answering a query about
PTB and may be less well represented in the contact lists of charities focused (in part) on preventing
PTB complications.
1 Strongly prefer vaginal
delivery
2 Moderately prefer vaginal
delivery
4 Moderately prefer CS
5 Strongly prefer CS







FIGURE 11 Method of birth preferences at 28 weeks’ gestation when vaginal delivery and CS are equally safe for
mother and CS is safer for the baby, but might make a future pregnancy and birth more risky.
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The data from our survey suggest the following:
l Many women are not in equipoise about the best method of birth for a preterm baby and have a
strong preference for either vaginal birth (most common) or CS.
l Women are more likely to choose vaginal birth at later gestations (than at other gestations).
l A strong preference for CS is more likely to be expressed at very early gestations (than at
other gestations).
l Women prioritise safety of the baby of the index pregnancy ahead of their own safety and against
safety of future babies.
These data were used to inform the protocol and the FGs, described in subsequent chapters.
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Chapter 5 The Delphi survey
Purpose and rationale
Our aim was to convene an interactive working group of stakeholders to determine what kinds of trials
still need to be carried out and which groups of women should be included in these trials.
Formal Delphi consensus methodology was used as a method of systematically collating expert consultation
and building constructivist consensus to resolve uncertainties. The Delphi technique is a flexible method
and can be adjusted to the respective research aims and purposes, as long as modifications are justified
by a rationale and applied systematically and rigorously. There was no intention to arrive at any more
than one trial option, but to agree on including or excluding different patient subgroups that could be
recruited to a trial. This report follows the recommendations of the CREDES (Conducting and REporting
DElphi Studies) guidance.
Planning and design
The multidisciplinary investigator team, including the two co-applicants representing patients and support
groups, developed, in an interactive virtual meeting, a longlist of clinical scenarios with equipoise, based
on the findings of the surveys described in Chapters 3 and 4 and a systematic literature search completed
in May 2019, which identified 54 relevant papers. The scenarios were piloted and edited by the lay
members of the investigator team.
In summary, the literature search identified the following prevalent issues: previous caesarean or not
(cited in seven papers), number of previous pregnancies (cited in four papers), body mass index (cited
in four papers), gestational age/degree of prematurity (cited in four papers), breech presentation
(cited in four papers) and multiple (multifetal) pregnancy (cited in four papers).
Other issues identified in the literature included hypertensive disease, gestational diabetes, advancing
maternal age, preterm rupture of membranes, chorioamnionitis, placental abnormalities, maternal
cardiac conditions, uterine abnormalities, presence of cervical cerclage, fetal growth disorders, cephalic
presentation, worrying cardiotocography trace of the fetal heart rate, presentation of twins, previous
vaginal birth, previous CS during the second stage of labour (associated with risk of recurrence of preterm
labour) and previous PTB. These issues informed decisions by the research team as to which scenarios to
include in the rounds, alongside findings from the survey and proposals by participants in round 1.
A two-round three-step Delphi consensus methodology was planned to score and reach consensus on
scenarios and subgroups to be included in a future trial. All stakeholder groups, including parents,
health-care professionals, researchers and health-care regulators, were invited to participate in the two
rounds of the Delphi survey (steps 1 and 2) and a final interactive consensus workshop (step 3).
The aim was for at least 40 participants in round 1 and more than 20 participants in round 2 and the
consensus meeting, with at least two or three representatives from each group of participants.
Definition of consensus
A prespecified scale and criteria were used for dropping and retaining items in the longlist.
Scenarios with (1) > 70% of participants scoring 7–10 and (2) < 30% of participants scoring 1–3 were
to be prioritised for discussion at the interactive consensus workshop.
Scenarios fulfilling only one of these two criteria were considered borderline.
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The literature search followed systematic search principles described in the Cochrane handbook.26
The longlist of scenarios was developed through the clinician and patient surveys.
A summary of the literature and survey findings was presented at the final consensus meeting
(i.e. step 3) using Microsoft PowerPoint® (Microsoft Corporation, Redmond, WA, USA).
External validation
The processes and results of all steps were presented to the Study Steering Committee, which made
comments and approved the framework for study conduct and interpretation, and, specifically,
recommended assessments for attrition bias.
Prevention of bias
To minimise attrition, DelphiManager (i.e. the software used to support the Delphi process)
automatically sent reminders every week to registered participants who did not complete each stage
and/or had missing data. The investigators did not participate in or influence the reminders.
Attrition bias was estimated by comparing the average scores for different groups of participants
between those who completed both rounds and those who completed only round 1 for evidence of
significant difference that implied biased participation in the second round as opposed to consensus.
Interpretation and processing of results
Consensus does not necessarily imply the ‘correct’ answer or judgement. Non-consensus and stable
disagreement provide informative insights and highlight differences in perspectives concerning the
topic in question.
Therefore, we decided a priori to retain all scenarios in both rounds and in all three steps, presenting
at the final meeting how scores had evolved over the consensus process, differences between participants
groups and the accompanying qualitative comments.
Study process and findings
Expert panel
The Delphi consensus invitees were agreed by the CASSAVA co-investigator team to include
UK-based preterm trial leads, members of the RCOG Preterm Birth Clinical Study Group, members
of the partners (i.e. Tommy’s and Bliss), other parent organisations (e.g. National Bereavement Care
Pathway charities), national stakeholders (e.g. NHS Improvement, NHS England and the Saving Babies’
Lives programme) and all participants in the previous clinician and parent surveys (see Chapters 3 and 4).
(Note that this is a more diverse group than described at grant application stage, when we described a
Delphi focused on clinicians only, but after reading survey results we felt that it would be helpful to get
perspectives from all stakeholders.)
Description of the methods
We used the web-based survey application (DelphiManager) that has been developed by the University
of Liverpool (Liverpool, UK) and adopted by the COMET (Core Outcome Measures in Effectiveness
Trials) initiative. The web-based Delphi survey is feasible, cost and time efficient and is accepted by
users. The survey was hosted within an online portal and infrastructure designed by the University of
Liverpool. Before entering the exercise, participants were asked to register, provide demographic
details and commit to two rounds.
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After the details of participants and the commitment to contribute to two rounds had been reviewed,
a unique identifier was allocated. The unique identifier anonymised participant responses but also
provided a means to send completion reminders.
Participants were asked to score each scenario using the GRADE scale (accessed online). This scale was
originally developed to score the quality of evidence of systematic reviews and has now been adopted
in other research studies using Delphi methods (e.g. core outcome sets). Participants were asked
‘[h]ow important is it to include the following scenarios in a randomised trial of mode of birth (caesarean/
vaginal) for a preterm baby’.
Free-text comments were also invited and facilitated by DelphiManager.
The Delphi questionnaire was piloted on the Study Management Group, the patient and public
involvement (PPI) panel and a sample of stakeholders to ensure the ease of completion by participants
prior to recruitment. This also ensured that the scenario terminology was understood by stakeholders
before allowing them to decide which scenario was important to them in the Delphi.
In round 1, participants received an e-mail linking to the web-based questionnaire embedded within
the study’s website. Initial questions included the option to add additional scenarios for use in round 2
before proceeding to scoring, as additional failsafe steps to identify any scenarios that are prominent
with experts and/or parents and should still be considered. Participants scored each scenario listed
using the Likert-type scale, as described above. The scores were summarised graphically and indicated
the whole groups’ and individual participant groups’ responses that were automatically collated by
DelphiManager, using its standard methodology.
After round 1, the data were analysed to produce a summary of results.
It was agreed in an interactive study management meeting that all scenarios would be carried forward
to round 2 in addition to scenarios proposed by the participants of round 1 after they had been
discussed by the study team and PPI representatives. An anonymous summary of the responses was
fed back to participants according to each stakeholder group. Participants were asked to, again, score
their preference to reach consensus.
An interactive consensus meeting involving key stakeholders took place following the completion
of the Delphi process to consider the scores and agree on inclusions and exclusions, including any
scenarios in Delphi round 2 where ‘no consensus’ was found. Only those stakeholders who completed
both rounds of the Delphi study were invited to participate to the final consensus meeting.
Procedure framework
Delphi survey rounds (steps 1 and 2)
It was agreed that participants would represent stakeholders in three groups (i.e. the maximum
allowed by DelphiManager):
1. parents
2. health-care professionals and researchers (academics)
3. health-care regulators and other stakeholders.
Although, ideally, equal numbers from the three groups would participate, it was agreed that this may
not be possible to ensure within the pragmatic constraints of the study. The rules specified that all
participants who completed the first two rounds were invited to the interactive workshop. In the lead’s
experience, the final workshop was likely to include comparable numbers from the three groups of
participants, even though the numbers in each group receiving the original invite to register to the
Delphi website may not have been identical.
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Each round was agreed to be left open for 2 weeks in view of time constraints. It was deemed
essential to complete analysis of the surveys before the workshop and it was expected that analysis
would take half a day.
Invitees received an e-mail with an invitation letter that provided a link to the web-based questionnaire.
A postal questionnaire was offered but not used by any invitee. All responders to both the clinician and
public surveys were invited to participate in the Delphi survey by accessing https://delphimanager.liv.ac.uk/
Cassava/Delphi, which was active from 1 November 2018 to 9 January 2019 (see Report Supplementary
Material 6). All participants who completed both rounds were invited to the Delphi consensus meeting in
London (held on 5 July 2019).
The scenarios were presented in domains (a fixed terminology by DelphiManager that was not possible
to amend). Scoring all scenarios on a page was mandatory by default.
The agreed domains, based on analysis of the previous surveys’ findings, were as follows:
l Domain A [spontaneous PTB with baby flexed breech (the baby is bottom first with its feet right
next to its bottom)] at:
¢ < 24 weeks’ gestation (A1)
¢ 24–25+6 weeks’ gestation (A2)
¢ 26–27+6 weeks’ gestation (A3)
¢ 28–36 weeks’ gestation (A4).
l Domain B [PTB for obstetric complications (e.g. pre-eclampsia and fetal growth restriction)] at:
¢ < 24 weeks’ gestation with any breech presentation (B1)
¢ < 24 weeks’ gestation with cephalic presentation (B2)
¢ 24–25+6 weeks’ gestation with cephalic presentation (B3)
¢ 26–27+6 weeks’ gestation with cephalic presentation (B4)
¢ 28–36 weeks’ gestation with cephalic presentation (B5).
Following the literature review, additional domains agreed were as follows:
l Domain C [women with previous caesarean birth(s) in spontaneous labour] at:
¢ < 24 weeks’ gestation with spontaneous preterm labour and cephalic presentation (C1)
¢ 24–25+6 weeks’ gestation with spontaneous preterm labour and cephalic presentation (C2)
¢ 26–27+6 weeks’ gestation with spontaneous preterm labour and cephalic presentation (C3)
¢ 28–36 weeks’ gestation with spontaneous preterm labour and cephalic presentation (C4).
l Domain D [women with previous caesarean birth(s) and indicated preterm labour] at:
¢ < 24 weeks’ gestation with indicated preterm labour (e.g. pre-eclampsia or growth restriction) (D1)
¢ 24–25+6 weeks’ gestation with indicated preterm labour (e.g. pre-eclampsia or growth restriction) (D2)
¢ 26–27+6 weeks’ gestation with indicated preterm labour (e.g. pre-eclampsia or growth restriction) (D3)
¢ 28–36 weeks’ gestation with indicated preterm labour (e.g. pre-eclampsia or growth restriction) (D4).
In round 2, participants were shown the distribution of scores from other participants, along with the
score that they attributed to each scenario. Only participants who had scored all scenarios in round 1
were automatically invited by DelphiManager to round 2. Round 2 participants were asked to reflect on
their responses, and re-score if they wanted to, having been shown the views of the other participants.
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DelphiManager facilitates this process by a simple setup followed by inbuilt functionality to calculate
the distribution of scores for a particular round. Unlike other online survey tools, the score distribution
is then automatically displayed to the participant in the next round, together with a reminder of their
own score. An example of what a participant might be shown in round 2 (of a Delphi with a single panel
throughout) is shown in Figure 12. Note that scenarios replaced outcomes.
In Figure 12, the participant’s score from the previous round is highlighted in yellow.
For the CASSAVA project, feedback in round 2 was intended to be split according to the three groups
described previously. However, it became clear after round 1 that some national stakeholder representatives
who had participated had declared themselves as a ‘health-care professional’ as opposed to a ‘stakeholder’.
It was decided to amalgamate these two groups, for a final split of (1) parents and (2) health-care
professionals/stakeholders.
Results were exported in a CSV file. Microsoft Excel® (Microsoft Corporation, Redmond, WA, USA) was
used to generate charts.
For statistical tests, we used Stata/SE® 15.1 (StataCorp LP, College Station, TX, USA).
Final consensus: step 3
The final consensus meeting was moderated by the Delphi lead, a clinical lecturer and a PPI representative.
As the purpose of this meeting was to elicit scenario(s) that would be desirable and feasible for a trial,
which meant the approach had to be inclusive as opposed to highly selective, participants were presented
with the results of the two rounds and were invited to discuss each scenario from the final list in detail.
Participants were invited to score any final uncertainties using the same scoring scale as in steps 1 and 2.
It was intended that the final output would be a couple of inclusive scenarios with clear exclusion criteria
(e.g. whether or not spontaneous cephalic labour with no comorbidity should be excluded).
FIGURE 12 Mock up of Delphi output.
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Results
Rounds 1 and 2
Eighty-six participants were included in round 1 (parents, n = 27; health-care professionals, n = 59).
Four parents did not score any scenarios and three parents scored only some (but not all) scenarios
and were not invited, by DelphiManager, to round 2. Ten parents did not continue after round 1.
Ten parents participated in both rounds. One health-care professional did not score any scenarios
and two health-care professionals scored only some scenarios and were not invited to round 2.
Twenty-eight health-care professionals did not continue after round 1. Twenty-eight health-care
professionals participated in both rounds. One new health-care professional who missed the first
round was allowed as an exception to join the second round for a total of 29 health-care professionals.
The total number of participants in round 2 was 39 (parents, n = 10; health-care professionals, n = 29),
of whom 38 completed both rounds.
After round 1, participants recommended a list of scenarios that were considered by the Study
Management Group and PPI representatives (Box 2).
BOX 2 List of scenarios
Suspected chorioamnionitis, 22–24 weeks’ gestion.
Suspected chorioamnionitis in labour (> 3 cm), cephalic presentation, > 24–26 weeks’ gestation.
Suspected chorioamnionitis in labour (> 3 cm), cephalic presentation, > 24–26 weeks’ gestation.
Suspected chorioamnionitis in labour (> 3 cm), cephalic presentation, > 28 weeks’ gestation.
Suspected chorioamnionitis, > 24–26 weeks’ gestation.
Suspected chorioamnionitis, 26–28 weeks’ gestation.
Suspected chorioamnionitis, > 28 weeks’ gestation.
Spontaneous PTB with extended breech presentation, < 36 weeks’ gestation.
Indicated PTB with extended breech presentation, < 36 weeks’ gestation.
Admission to NICU in term babies.
Footling breech scenarios.
Abnormal middle cerebral artery doppler studies or ratio.
Previous laser twins, first twin cephalic, spontaneous labour.
Preterm twins with variations on presentation of the first twin, as per previous questions.
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The investigator team decided to add four more scenarios to round 2 of the Delphi (see bold text
in Box 2). As the DelphiManager website did not allow for the inclusion of additional domains after
round 1, it was decided to include the scenarios under domain A.
There was evidence of consensus over the two rounds, with scenarios more likely to be included after
round 2 than after round 1 (Figure 13).
Induction of labour.
Augmentation of labour.
Spontaneous labour, twin pregnancy, 25–28 weeks’ gestation.
Patient with lethal fetal anomaly at any gestation between 24 and 36 weeks’ gestation.
NICU, neonatal intensive care unit.
Bold text indicates scenarios that were added for round 2 of the Delphi.








































































































































































































































































































































































































































































Indicated birth Previous CS Previous CS
FIGURE 13 Recommended scenarios in Delphi rounds 1 and 2.
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Eighty-one (10.2% of 798 individual scores – 21 scenarios × 38 participants) individual scores were
different between rounds 1 and 2.
After round 2, few scenarios fulfilled criteria for exclusion, with most scenarios either qualifying for
exclusion or being borderline (Figure 14).
When comparing parents alone with the overall scores, parents were more likely to score borderline
scenarios for inclusion in a future trial {e.g. all D scenarios [women with previous caesarean birth(s)
and indicated preterm labour]} (Figure 15).
Examples of comments from the Delphi survey rounds are included in Appendix 2.
Attrition bias
Forty participants (n = 12 parents; 30%) completed only round 1 and 38 participants (n = 10 parents;
26%) completed both rounds. One participant completed only round 2.
There was no evidence of significant attrition bias (Figure 16). Scores were not significantly
different between those participants who completed both rounds and those who completed only
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FIGURE 14 Percentage of participants scoring 1–3 (left axis) vs. 7–9 (right axis).
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FIGURE 16 Attrition between Delphi rounds.
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Consensus workshop (step 3)
Twenty-two experts attended the consensus workshop, including five parents/parent organisation
representatives (23%) and two trial managers, as well as one observer.
The areas that required further discussion during the meeting were summarised as follows.
Should the following groups of women be included:
l Women at ≥ 24 weeks’ gestation with a flexed, footling or extended breech presentation and in
spontaneous labour.
l Women at < 24 weeks’ gestation
l Women in spontaneous preterm labour with a cephalic presentation.
l Women who have suspected, or confirmed, chorioamnionitis and cephalic presentation.
l Women expecting twins.
The group were asked to think about these areas for the discussions. The Delphi survey scores
indicated that women at < 24 weeks’ gestation should not be included in the trial. However, the
group reflected that this did not demonstrate overall understanding of the purpose of research,
which was to improve outcomes, or recognition that neonatal care and survival of babies born at
23 and 22-weeks’ gestation has improved. Parents who participated in the surveys were more
inclusive than staff.
Strengths and weaknesses
Besides attrition, the process was prone to the weaknesses of the Delphi process in general, including
selection bias (i.e. interested clinicians and patients more likely to participate), language and internet
familiarity limitations, and arbitrary consensus criteria.
To optimise the reliability of the findings, we used criteria established and widely used in the
literature. We supplemented and enriched the findings of the Delphi with subsequent qualitative
research, including with under-represented populations. We calculated and showed that there was
no significant attrition bias for professionals and parents alike. Finally, we argue that the purposive
sampling technique intentionally recruited those professionals with established interest and expertise,
as they are more likely to represent those likely to participate in a future trial as local principal
investigators. Parent participants likely represent either potential participants in a trial or
lay co-investigators.
TABLE 5 Delphi round scores from health-care professionals and parents
Participant
Number of participants
observed Mean SE SD 95% CI (p-value)
Health-care professionals
Both rounds 28 6.45 0.32 1.73 5.77 to 7.12 (0.0546)
Round 1 only 30 5.5 0.35 1.94 4.77 to 6.22
Parents
Both rounds 10 7.47 0.41 1.32 6.52 to 8.41 (0.8062)
Round 1 only 14 7.33 0.37 1.39 6.52 to 8.13
SD, standard deviation; SE, standard error.
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Discussion key points
l All participants agreed that it was difficult to know the right thing to do without evidence, and that
how to present this information to women should be explored. It is important to do this well.
l All participants agreed that the CASSAVA project team would need to look at how to present
evidence to women in high-stress situations. Communication is important, as women want
confidence in the discussion and clinicians need to be honest in their understanding and experience
to help facilitate and agree the pathway of choice.
l Where possible, it would be preferable to speak to women early in pregnancy or labour.
Parents wanted to know about the risks of PTB early, as they felt that it was not included in
their antenatal care. Labour is not the best time to present this information, as women are
in pain and may have received opiate drugs in labour and (arguably) are not always able to
make effective decisions. Antenatal literature should contain information about PTB and birth
options should be discussed.
l The trial design should be the cleanest and clearest design to ensure that women who may benefit
are not excluded, including women expecting twins.
l Does a woman’s obstetric history change what we think about inclusion?
l Trials should provide capacity for clinicians to randomise at lower gestations (i.e. 22–24 weeks’ gestation).
l If the situation is life-threatening (e.g. antepartum haemorrhage) then women should not be
approached to take part in a trial.
l Communication is key, especially in the antenatal period. Communication needs to be very clear
about possible emergency procedures if the scenario changes and the attending clinician and
pregnant woman believe that the randomised mode of delivery is not appropriate.
l Twins should be included, as trials need to be pragmatic and inclusive.
It was provisionally agreed that women with the following clinical scenarios should also be included in
further stages of the CASSAVA project:
l Women with a baby with flexed or footling breech presentation.
l Women at > 24 weeks’ gestation with chorioamnionitis and a malposition (e.g. breech).
l Women with an indicated birth of < 24 weeks’ gestation who have had a previous CS.
l Women in spontaneous cephalic preterm labour.
Using an online anonymous voting system [URL: www.wooclap.com (accessed 1 September 2021)],
the participants scored the following scenarios:
1. Women at ≥ 24 weeks’ gestation with an extended breech presentation and in spontaneous
labour (score = 7.2).
2. Women in spontaneous labour at < 24 weeks’ gestation (score = 7.9).
3. Women with chorioamnionitis and a cephalic presentation (score = 7.0).
4. Women expecting twins (score = 7).
(Note that it was agreed a priori that if there was a score of > 5, then there was agreement on
balance that the scenario should be included. If there was a score of > 7.5, then there was
strong agreement.)
All scores were in favour of allowing these groups to participate.
Additional discussion took place around specific scenarios that are described below.
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Extended breech
Generally, the group thought that there would be more equipoise for staff when the gestation was
< 30 weeks. However, it was agreed that women in spontaneous labour with an extended breech
presentation should be included up to 36+6 weeks. There were also other issues to consider:
l A competent person needs to be available to perform the CS or a breech vaginal birth.
l The lack of experience of breech deliveries may be a concern for staff and may result in poor
outcomes for the trial and site.
l Staff would need to provide women with clear explanations, including options to deliver the baby,
if complications develop.
l Is a RCT the right answer for parents? The word ‘random’ has different implications for parents;
therefore, will parents be concerned that you are gambling with their babies and their well-being?
Spontaneous labour at < 24 weeks’ gestation
There are improved survival rates and it is challenging to conduct a CS at the lower gestations, as
there are risks for the mother and baby. However, the potential benefits for the baby could be greater.
The consensus was that we should be as inclusive as possible, with a cut-off of > 22 weeks’ gestation.
Review of maternal morbidity rates is required, as there are potentially high risks for the women,
especially if only a classical section is available and this would prevent future vaginal deliveries.
The following question/issues should be considered:
l Does a site (centre) have a policy to resuscitate babies at < 24 weeks’ gestation?
l Classical section competency and information given to women about the risks is required.
l Ethics considerations of doing this before a baby is legally viable in the UK.
Chorioamnionitis with a cephalic presentation preterm
The group agreed women with chorioamnionitis and a cephalic presentation should be included if in
spontaneous labour. The condition must be defined in standard operating procedures.
Using an online anonymous voting system [URL: www.wooclap.com (accessed 1 September 2021)],
the workshop participants scored the following scenarios:
1. Women at ≥ 24 weeks’ gestation with an extended breech presentation and in spontaneous labour
(score = 7.8).
2. Women in spontaneous labour at < 24 weeks’ gestation (score = 8.0).
3. Women with chorioamnionitis and a cephalic presentation (score = 8.4).
4. Women expecting twins (score = 8.8).
(Note that there were 20 votes, in total, from 22 attendees, as one attendee had left before voting and
one attendee could not access the server.)
Items for the trial team to consider are as follows:
l The protocol needs to clarify study procedures, but be flexible enough to permit local opt-outs.
l Sites require staff with the skills and experience for breech presentation. Perhaps sites could choose
to recruit to the scenario of extended and/or flexed breech, with the ability to opt out of some of
the other scenarios.
l Staff need to be able to explain both options competently, including why they are in equipoise.
l The planned birth option compared with the spontaneous preterm labour plan should be investigated.
l Timing between discussion of options and randomisation should be considered.
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Strengths and limitations
We acknowledge that participation in the interactive working group was restricted to English-language
speakers because of costs. We used FGs to ascertain the views of specific ethnic minority populations
that were unable to participate in the working group.
The process was limited by the inflexibility of the Delphi website and software, for example the lack
of capacity to add new domains. The support provided for DelphiManager was not 24 hours per day,
7 days per week (24/7), which further limited its flexibility. However, there was excellent participation
in all three steps by health-care professionals and parents alike, with no evidence of attrition bias.
Conclusions
The Delphi process was deemed successful. Consensus was reached in the scenarios prioritised in
the previous surveys, those added after the literature review and those added after round 1. Parents
wanted most scenarios included in further research. Comments by the participants in the two survey
rounds (via free text) and the consensus workshop helped provide context to the information input
into the next stage (i.e. the qualitative research).
DOI: 10.3310/hta25610 Health Technology Assessment 2021 Vol. 25 No. 61
Copyright © 2021 Norman et al. This work was produced by Norman et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
39

Chapter 6 Development of a short
trial protocol
Introduction
A short trial protocol was developed for a trial that we called CASSAVAplus. The purposes of this
protocol were specifically to inform a ‘vignette’ for discussion with potential trial participants, and to
provide a prototype for discussion with clinicians around recruitment and conduct of a trial. It was not
necessarily intended that CASSAVAplus should be the final protocol in any future study.
The trial protocol was designed to determine the best MoB for women and babies in preterm labour.
It was developed after the clinician and parent surveys and the Delphi consensus procedure (and was
informed by the results of these activities), but before the qualitative work described in the next
chapter. The CASSAVAplus protocol was developed by the investigator team (using their expertise and
experience in clinical trials for PTB), but without the wider stakeholder discussions that would normally
take place in designing a trial. The primary outcome was chosen as one that observational studies
have suggested could be affected by mode of PTB and one that would likely affect either clinician or
parent choices on MoB. A 5% difference in the rate of primary outcome was agreed by the investigator
group as being clinically meaningful and used to calculate the sample size. A fuller version of the
CASSAVAplus protocol is described in Appendix 4.
For ease of reference, the ‘PICO’ (population, intervention, control/comparison, outcome) for
CASSAVAplus is described below.
Participants
Inclusion criteria for approaching potential participants
l Women at risk of spontaneous preterm labour, including:
¢ women with a previous PTB before 34 weeks’ gestation (spontaneous or induced)
¢ women who have had cervical surgery (cone biopsy or cold coagulation)
¢ women with a short cervix or positive fetal fibronectin prior to 24 weeks’ gestation.
l Women presenting with signs or symptoms of preterm labour (e.g. contractions, lower abdominal
pain, mild per vaginam bleeding, show).
l Women presenting with preterm premature rupture of membranes.
Or:
l Women for whom a clinician decision has been made jointly by the clinician and the woman for
elective preterm delivery between 22+0 and 36+6 weeks’ gestation.
Exclusion criteria for approaching potential participants
l Maternal or fetal indications for CS.
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Inclusion criteria for randomisation
l Women 22+0 to 36+6 weeks’ gestation with signs and or symptoms of labour, including:
¢ women with cephalic, flexed breech or extended breech presentation
¢ women with a live baby in whom it is anticipated resuscitation will be attempted.
Or:
l Women 22+0 to 36+6 weeks’ gestation in whom elective preterm delivery will be performed in the
next 72 hours, including:
¢ women with cephalic, flexed breech or extended breech presentation
¢ women with a live baby in whom resuscitation will be attempted.
Exclusion criteria for randomisation
l Triplets and higher-order multiples.
l Diagnosed intrauterine death.
l Advanced labour, such that CS cannot be performed safely (at clinician’s discretion).
Intervention
The intervention was CS.
Comparator
The comparator was vaginal birth.
Outcomes/end points
Primary outcome
Neonatal composite of alive at 6 months after birth or to home discharge (whichever is sooner) and
without significant IVH (defined as grade 3 or 4 IVH) or cystic periventricular leukomalacia.
Secondary outcomes
Maternal: major maternal morbidity (as a composite and as individual components)
l Post-partum haemorrhage ≥ 1 litre.
l Admission to the main intensive care unit for > 24 hours.
l Bowel injury requiring repair.
l Bladder injury requiring catheterisation for > 48 hours.
l Other organ damage.
l Postnatal anaemia < 70 g/dl (or requiring a transfusion).
l Postnatal infection (sepsis) requiring intravenous antibiotics for > 48 hours.
l Anal sphincter injury.
l Postnatal depression requiring inpatient admission.
l Hysterectomy.
l Return to theatre for any other reason.
l Confirmed thromboembolic disease.
l Post-traumatic stress disorder.
l Hospital stay of ≥ 7 days.
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Neonatal
l Incidence of Apgar scores of < 7 at 1 and 5 minutes.
l Early mortality (i.e. < 72 hours of life).
l Mortality before 6 months of age/discharge home alive.
l Significant IVH (defined as grade 3 or 4 IVH).
l Cystic periventricular leukomalacia.
Costs
l Costs of major maternal morbidities from recruitment to 6 months postnatally.
l Costs of major neonatal morbidities from recruitment to 6 months postnatally.
A fuller description and a flow chart of CASSAVAplus is shown in Appendix 3, Figure 17.
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Chapter 7 Qualitative research
Introduction
As noted earlier, the research evidence3,4 on which health-care professionals and/or women make their
decisions with regard to MoB in PTB is inconclusive. Considerable effort has been made to resolve the
resulting clinical uncertainties, with at least six RCTs attempted to date.3 However, all those trials were
stopped early, reporting difficulties with recruitment (collectively enrolling just 122 women). Although
limited information is available on why recruitment to those trials proved so challenging, health-care
professionals’ reluctance to randomise eligible women was reported as being an important factor in
some instances.3 Survey data from a study exploring willingness to participate in a hypothetical trial
suggests that pregnant women may be similarly reluctant to enrol,27 although trials comparing MoB at
term have recruited adequately, albeit with the involvement of many sites (around 120) in many (25+)
countries.13,18 The success of those trials suggests that, with appropriate design and resourcing, MoB
trials are feasible, which is a view also expressed by Alfirevic et al.3
Over recent years, qualitative research, drawing on the perspectives of both health-care professionals
and patients, has played an increasingly important part in progressing understanding of why clinical
trials succeed (or fail). For example, such research has shown how lack of or unstable equipoise (Box 3)
regarding trial interventions may affect health-care professionals’ engagement.30–32 Qualitative research
has also highlighted how more pragmatic resource-related concerns (shortfalls) may undermine even
committed health-care professionals’ support for trials.33 Research involving patients has provided
further insight into the barriers to and facilitators of trial recruitment more generally and in particular
specialisms/areas.34–36
Given the potential challenges of recruiting into a trial of MoB in PTB, and to help inform decisions
about whether or not such a trial should go ahead in the future, our qualitative study sought to
address the following aims.
BOX 3 Concept(s) of equipoise
Equipoise: a slippery concept
The term equipoise refers to a situation where clinicians and/or patients are unable to determine the
superiority of, and have no preference between, different interventions or care options.28 Clinical equipoise,
sometimes referred to as ‘community equipoise’, is said to exist when the medical profession collectively
agrees that insufficient evidence exists to determine the superiority of one treatment option over another.29
A RCT can be justified (only) when clinical equipoise exists. However, although clinical equipoise may
provide the driving force behind a RCT, individual practitioners may hold competing views and have
preferences for care that are at odds with the collective viewpoint (i.e. they may lack individual or personal
equipoise). The degree to which individuals are uncertain about the effects of interventions may vary and,
to complicate matters further, it is possible to be uncertain but still not be in equipoise.30
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Aims
1. To determine (1) whether or not health-care professionals would be willing to recruit women into
the proposed trial and (2) whether or not women would be willing to participate.
2. To explore if (and what) aspects of the trial’s design would need to change to make it more
acceptable to health-care professionals and women.
3. To determine whether or not there are any practical, logistical or other challenges likely to impede
trial delivery, and establish what resourcing and other support health-care professionals might need
to overcome these.
4. To understand and explore the potentially distinctive challenges of recruiting ethnic minority
women into the trial, and to establish any additional resourcing and support needed to optimise
these women’s participation.
Although we were successful in delivering aims 1–3, for reasons detailed below (specifically, the impact
of the COVID-19 pandemic on data collection activity) we were able to address aim 4 less satisfactorily.
Methods
Overview
The qualitative substudy featured an emergent, inductive design, involving an iterative and reflexive
approach to sampling, data collection and analysis. Two methods were employed: (1) semistructured
interviews to solicit health-care professionals’ perspectives on the hypothetical trial and (2) FGs
to gather the views of women. Data collection was undertaken in the UK from October 2019 to
March 2020 when research activity (i.e. data collection) was suspended by the sponsor because of the
COVID-19 pandemic. We provide a detailed description of our methods, in accordance with COREQ
(COnsolidated criteria for REporting Qualitative research),37 below.
Interviews with health-care professionals
Interviews with health-care professionals explored health-care professionals’ views about a hypothetical
trial protocol (HTP), which was developed by the co-investigator team in the light of findings from earlier
phases of the study, as described in Chapter 6. Two versions of this HTP (i.e. summary and full) were
produced (see Appendices 2 and 3), with both written in a style familiar to health-care professionals.
We aimed originally to discuss the HTP with approximately 25 health-care professionals; however,
when research activity was suspended, we had completed 24 interviews. We are reasonably confident
that data saturation was reached in these health-care professional interviews.
Sampling: health-care professionals
A purposive sampling strategy was discussed and agreed with the co-investigator team. The goal of
the purposive sampling strategy was to capture the perspectives of health-care professionals who had
experiences relevant to the HTP and who had worked in a range of roles and maternity settings across
the UK. As the HTP included PTB at lower gestations (down to 22 weeks’ gestation), we prioritised
health-care professionals working in, or with experience of, settings providing level 3 neonatal care
(i.e. offering an extended period of intensive care to neonates, e.g. because of PTB at < 27 weeks).
Given that obstetricians are key to the recruitment of women into intrapartum trials, a decision was
made to ensure good representation of this professional group.We also decided to include neonatologists,
given their role in counselling parents (in particular, about neonatal care) prior to PTB. As midwives play
a role in supporting women at risk of and/or during PTB,38 and research midwives play an important
part in the delivery of trials,39 our sampling strategy was further designed to include both clinical
midwives (working on labour wards/emergency admission units) and research midwives. We aimed to
involve health-care professionals of all types and with varying lengths of clinical experience and levels
of responsibility.
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Recruitment: health-care professionals
Health-care professionals completing the phase 1 survey were asked to indicate their willingness to be
contacted about participation in a telephone interview. Seventy-eight individuals working in a variety
of roles agreed to this and the CASSAVA study administrator e-mailed selected respondents an
invitation to take part in an interview. Attachments to the e-mail included a participant information
sheet and an opt-in form that were returnable directly to the qualitative research team.
In addition to approaching health-care professionals responding to the phase 1 survey, and as proposed
in our original grant application, the qualitative research team identified and recruited other potential
study participants using snowballing techniques. This approach involved asking interviewees to forward
study information to colleagues who met our sampling criteria and might, potentially, shed light on
emergent issues.40,41 A breakdown of health-care professionals recruited through each of the two routes is
provided in Table 6.
Data collection
Health-care professionals who agreed to take part in an interview were sent information about
the hypothetical trial prior to the interview. This information took the form of a three-page
summary document (see Appendix 3), which they were told would form the focus of the interviews.




Recruitment from phase 1 survey
Number of health-care professionals from phase 1 survey indicating willingness to be
contacted regarding interview
78
Number of health-care professionals from phase 1 survey currently practising in settings





Number of health-care professionals from phase 1 survey practising in settings with
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Health-care professionals were also sent a more detailed 14-page document (see Appendix 4) that they
were invited to consult if clarification was needed. All interviews were undertaken by Sushila Chowdhry, a
social scientist with a background in health care. The interviews took the form of a ‘guided conversation’,42
loosely following a topic guide (see Report Supplementary Material 7) focused on key features of the HTP.
The topic guide was developed with input from the co-investigator team and informed by the wider (trials)
literature. It was revised as data collection progressed, in keeping with the inductive approach utilised in
the study.43 For example, we had originally intended to explore, with health-care professionals, the
potentially distinctive challenges of recruiting ethnic minority women into the trial (and any resourcing
and support that might mitigate this). However, this area of enquiry was de-prioritised because of the
complexity of the trial design we were tasked with exploring with health-care professionals, health-care
professionals’ highly qualified support for the proposed trial and the limited time most interviewees
could commit. Therefore, a pragmatic decision was made, relatively early on in data collection, to focus
interviews on key elements of the trial design. Interviews were conducted by telephone, between
October 2019 and March 2020, at times convenient to participants. The interviews lasted 30–64 minutes
and informed consent was obtained.
Data analysis: health-care professional interviews
All interviews were transcribed verbatim by a professional transcription company. Our approach to
data analysis observed the principles of inductive analysis and involved ‘discovering patterns, themes,
and categories in one’s data’.43 To achieve this, transcripts were read and re-read by three members of
the qualitative team (SC, RIH and JL), and emergent patterns and ideas were discussed before the interview
data were systematically coded and codes sorted into themes.44 Sushila Chowdhry and Ruth I Hart then
produced detailed analytical reports, which provided a basis for discussion with the wider qualitative
research team and were used in the writing of this final report. Team discussions considered areas of
convergence and divergence, providing a catalyst for further analysis and increasing the dependability
of the final analysis.45 This collaborative and dialogic approach encouraged reflexivity (i.e. attention to
how personal values and assumptions may have had an impact on research activity and data interpretation).
Qualitative software (NVivo version 11) was used to facilitate data coding and retrieval.
Focus groups with women
We aimed originally to undertake six to eight FGs, involving women with diverse pregnancy experiences
and including three groups dedicated to ethnic minority women. Regrettably, only our pilot group (PG)
plus two actual FG discussions (FGs 1 and 2) had been conducted when research activity was suspended
in March 2020. Further groups, which were in advanced stage of organisation, had to be cancelled
(see below for more information about the completed and planned groups).
Consultation to see if virtual groups would be acceptable
As some of the women from the cancelled groups suggested doing FGs using virtual methods, we
submitted a proposal to the sponsor (on 15 April 2020) to conduct the remaining groups virtually
(i.e. online). The sponsor assessed our submission as a (non-substantial) amendment and advised that
further ethics/governance approval would be required. Alongside this, we liaised with Bliss’ Insight and
Involvement Group (made up of a broad range of parents with neonatal experience) to seek members’
perspectives on the idea of conducting virtual FGs. Sixteen women offered feedback. Although these
women were supportive of the idea of FGs being carried out virtually, they also raised significant concerns.
Specifically, there were some worries that participants, especially those currently pregnant, might be
experiencing heightened anxiety due to the pandemic, which could potentially be compounded by research
participation. It was noted that should a woman become distressed during a virtual FG the facilitator
would be unable to take her to a private space and offer comfort and information. These concerns led
the qualitative and wider co-investigator group to conclude that it would be ethically problematic to
collect data using virtual methods. Data collection was, therefore, discontinued.
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Sampling: women
Guided by discussions with our PPI group (organised through the CASSAVA project’s partner organisations
and the wider co-investigator team), we developed a detailed sampling strategy. To elicit a diversity of
perspectives on the hypothetical trial, we aimed to sample for women who had previously experienced
either spontaneous or planned PTB; women who were contemplating pregnancy, or were currently
pregnant, and judged low risk for PTB; women who were pregnant and considered at high risk of PTB;
and women who had experienced elective and/or emergency CS in PTB. Originally, it had been our
intention to conduct three dedicated FGs with women from ethnic minority backgrounds [i.e. a group
with women from Poland, a group with women of Pakistani ethnicity (Urdu/Punjabi speakers) and a
group involving women of Somalian ethnicity], which we were intending to recruit from Bristol where
a large Somalian ethnic population resides and one of our co-investigators (DS) was based when the
original grant application was submitted. However, owing to Dimitrios Siassakos changing institutions to
University College London (London, UK), a decision was made to substitute the group involving women
of Somalian ethnicity with one comprising women of Indian ethnicity.
Recruitment: women
As recommended by Kitzinger,46 we aimed to recruit four to eight women to each group. In line with
our original application, women were recruited via a variety of intermediaries and methods, and with
the support of our partner organisations. For example, Bliss and Tommy’s used their established social
media networks to advertise the study.
Our PG targeted women of Indian ethnicity who were able to communicate in English and had previous
experience of PTB. Participants were recruited by a CASSAVA project research midwife based in a large
tertiary maternity care setting in England. Potential participants were provided with written information
(in English) about the study, including a participant information sheet and an opt-in form that was directly
returnable to the qualitative research team.Women interested in participation could also contact the
research midwife for further information. Five women agreed to participate, with three ultimately taking
part (one woman changed her mind about participation prior to the event and one woman did not attend
on the day).
Focus group 1 targeted women of Indian ethnicity who were able to communicate in English, with
and without direct experience of PTB. Participants were recruited via our partner organisations, aided
by a group member sharing the study information via social media (including school Facebook groups).
Participants were asked to contact the qualitative research team for further information. Women
were then sent an e-mail with the study information (in English) and invited to make contact for further
information. Six women agreed to participate, with four women actually taking part (one woman changed
her mind about participation prior to the event and one woman did not attend on the day).
Focus group 2 targeted women of Polish ethnicity with and without direct experience of PTB, including
women who were contemplating pregnancy. It was organised by a bilingual Polish researcher (Ania Zubala)
who recruited participants from actual and virtual Polish community groups, venues and forums.
Basic information about the study, written in Polish, was displayed in hairdressers and shops attracting
a Polish clientele and distributed via the internet and social media. Women interested in participating
were advised to contact the bilingual researcher for further information. Nineteen women did so and
were provided with a study information pack, written in Polish, with nine women returning the opt-in
form. Nine women agreed to participate, with six women actually taking part (two women withdrew
because of difficulties with childcare and one woman withdrew for an unspecified reason).
Recruitment into FGs 3–5 was under way when data collection was halted. One of these groups
targeted women currently pregnant and attending a specialist clinic for women at high risk of PTB,
another targeted women with previous experience of PTB and the final group was for women of
Pakistani ethnicity (with recruitment via a bilingual Pakistani researcher). Fourteen women had
indicated their agreement to take part in one of these FG discussions.
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Data collection: women
The PG discussion was conducted on 21 November 2019 and FG 1 and FG 2 discussions were
conducted on 4 February 2020 and 17 February 2020, respectively. All discussions took place in
accessible and suitably private venues. At the start of each discussion, confidentiality was discussed
and agreement reached on appropriate conduct. Women were asked to provide information, in
confidence, about their reproductive history, ethnicity, religion, age and occupation. Some women
chose not to share all aspects of this information and such decisions were respected. The PG and FG 1
discussions were conducted in English, whereas the FG 2 discussion was conducted mostly in Polish.
Focus group participants were presented with a hypothetical story (a vignette) and a series of questions,
a method described by O’Dell et al.47 The vignette (see Report Supplementary Material 8) described
a situation in which a woman in spontaneous preterm labour was admitted to hospital, approached by a
doctor and asked to consider taking part in the hypothetical trial. The vignette was designed to reflect a
relatively common clinical scenario (i.e. spontaneous preterm labour at 30 weeks’ gestation). The vignette
included an explanation of randomisation and covered important aspects of trial participation, such as
the right to withdraw. Participants were asked to draw on their own experience and imagine how the
woman in the vignette might respond to a series of questions (see Report Supplementary Material 9).
These questions were designed to help the group explore and discuss trial participation in various clinical
situations and at different gestations. The vignette and other FG materials were reviewed by a PPI group
organised through one of the CASSAVA project’s partner organisations (Bliss) and also by one of the
co-investigators, who checked the information for medical accuracy.
The discussion was facilitated by a qualitative researcher (SC, or, in the case of the Polish women’s FG,
Ania Zubala), with the assistance of a colleague. Participants were encouraged to discuss the issues
with each other, rather than with the facilitators.48 Care was taken to ensure that all women had
opportunities and felt able to contribute to the discussions. FG discussions averaged 90 minutes and
were digitally recorded. Field notes were also taken.
Data analysis: focus groups with women
The first two transcripts were transcribed verbatim by a professional transcription company, whereas
the transcript from FG 2 was translated and transcribed from Polish into English by its facilitator
(Ania Zubala). In the light of the limited data we were able to collect, we decided to include data from
the PG in our analysis. Consent to this had been obtained from PG participants at the start of their
discussion. Our approach to analysis was similar to that described in relation to the health-care
professional interviews (see Data collection), with close attention being given to how participants thought
the character in the vignette ‘would’ or ‘should’ act and how they themselves would feel and act in a
similar situation. We considered both the views of individual participants and the convergence and
divergence at the group level.49 We sought to identify both similarities and differences in women’s
perspective(s) on being invited to take part in the proposed trial, including their impressions and concerns,
and any changes that they thought might promote women’s participation. Particular attention was paid
to potentially modifiable concerns relating to the conduct/delivery of the trial (e.g. informed consent
processes). To enhance rigour, transcripts were read, data were coded and analytical reports were
produced by two members of the team (SC and RIH). These reports were reviewed by, and discussed
with, the wider qualitative team (JL and NH) before being used in the writing of this final report.
Results
We now report our key findings in relation to our four overlapping research aims. We focus principally
on the findings from the interviews with health-care professionals because of the limited number of
(women able to take part in) FGs. Some tentative insights from the FGs are reported at the end of the
Results section.
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Part 1: findings from interviews with health-care professionals
Achieved sample: health-care professional interviewees
Our final sample included health-care professionals with varying interests, levels of expertise and
experience of working in more and less specialist sites. Further information is provided in Table 7.
Individual interviewees were given a unique reference, the initial letter(s) of which signifies their role
[i.e. OB = obstetrician, N = neonatologist, (R)M = (Research) midwife]. Quoted interviewees are not
further characterised in this report, as the size of the pool from which we were recruiting means such
information could conceivably compromise participant anonymity.




Obstetricians (N = 12)
Consultant: obstetrics/fetal medicine 5
Consultant: obstetrics and gynaecology 2
Specialist trainee: obstetrics and gynaecology (all ST3–ST6) 5
Identifying/identified as a clinical academic 8
Experience of recruiting to clinical trials 12
Experience of PTB at < 28 weeks’ gestation 12
Current practice setting
Tertiary care 10
Level 3 neonatal care 10
Level 2 neonatal care 2
Neonatologists (N = 5)
Consultant: neonatology 3
Consultant: paediatrics (specialising in neonatology) 2
Identifying/identified as a clinical academic 1
Current practice setting
Level 3 neonatal care 5




Senior research midwife 1
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Aim 1a: determine whether or not health-care professionals would be willing to
recruit into the proposed trial
Health-care professionals would welcome improved evidence, but anticipate difficulties
producing this
Health-care professionals largely welcomed the idea of a trial of MoB preterm (Box 4). Health-care
professionals described the current evidence base for decision-making about MoB in PTB as suboptimal,
with many highlighting gaps that they would like to see filled:
We really like guidelines and proformas and evidence-based work, and it doesn’t really feel like that is at
the moment . . . it would be really good to have some really strong evidence to actually base our practice
on, rather than just kind of [the] personal preference of the consultant.
M01
Health-care professionals described how the current deficiencies in evidence led to uncertainty (for
both health-care professionals and pregnant women), difficulties facilitating informed decision-making
and, potentially, suboptimal clinical outcomes for some women and babies. Therefore, interviewees
were largely supportive of the idea of a trial:
We need really good evidence to drive change, so that a substantial number of women and babies can get
better outcomes.
OB6
However, although health-care professionals were supportive, in principle, of a trial, interviewees
envisaged significant challenges to delivering one as proposed in the HTP:
It’s a really good topic . . . it would be great to have the evidence . . . However, I think gathering the
evidence is going to be difficult.
RM03
These challenges related mostly to the existence of strong and divergent views in the health-care
professional community about the relative merits of vaginal birth and CS in PTB, and associated
variations in practice (discussed in detail below). In addition, health-care professionals shared
doubts about aspects of trial design, which they suggested might undermine wider support for
the proposed trial and raised other, more pragmatic, concerns. These issues are explored in
subsequent sections.
BOX 4 Health-care professionals’ initial comments on a trial of mode of delivery
Key points
Health-care professionals largely considered the existing evidence base regarding MoB preterm as
deficient, and consistently said that they would welcome improved evidence. However, many health-care
professionals anticipated that delivery of the proposed trial would present significant challenges.
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Health-care professionals report strong mode of birth preferences (i.e. areas where
personal equipoise is lacking)
Despite, or because of, the gaps in the evidence base, interviewees said that they, and/or their colleagues,
had developed quite strong and ‘fairly fixed’ (OB1) views about the best or safest MoB, and that views
these guided their practice (Box 5). Interviewees also noted how these opinions and associated practices
varied between, and sometimes within, centres:
Practice does . . . seem to be different in different centres. And quite strong, different attitudes in different
centres, with not a very good evidence base to support it either way.
N02
Women could, theoretically, go down one route or the other if they just rocked up to a different hospital,
and had a different person on shift.
OB6
Factors influencing the development of mode of birth preferences
Reflecting on how these different MoB preferences had emerged, interviewees identified several
overlapping influences. These included unit/service norms, personal skills and confidence, direct experience,
and memorable local and/or high-profile national cases. The first of these influences (i.e. unit/service
norms) was portrayed as playing a powerful role in shaping – sometimes by constraining – obstetricians’
(and others’) practices and preferences. Although some interviewees described how practices and
preferences had developed through reflection and debate, others highlighted tradition and hierarchy as
being pivotal influences:
It will be very much the culture of the hospital, how the deliveries are done . . . the way they’ve always done it.
OB9
Several obstetricians noted how senior consultants’ preferences regarding MoB effectively determined
the training experiences of junior staff:
Trainees get trained up with what the consultants are comfortable with.
OB12
For instance, it was noted that where there was a strong tradition of delivering breech presentations
by CS, encouragement to specialist trainees to consider vaginal birth, and opportunities to develop the
necessary skills, could be very limited.
(Lack of) skills and confidence were further highlighted as important factors, and were implicated,
in particular, in some individuals’ reluctance to undertake breech vaginal deliveries:
It’s meant to be evidence-based medicine, but you do . . . what you’re most comfortable with.
OB12
Doctors have become de-skilled in breech vaginal deliveries . . . and they don’t have the confidence or skills.
RM01
BOX 5 Health-care professionals’ MoB preferences
Key points
Health-care professionals reported the existence of marked preferences for MoB in different clinical scenarios.
These preferences appeared to emerge from a variety of sources, including unit/service norms, personal
skills and confidence, direct experience, and memorable local and/or high-profile national cases. Although
health-care professionals reported differing preferences and practices, some broad patterns were evident.
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Personal experience was also said to play a powerful role in shaping many care decisions. Interviewees
noted, for example, how difficult and/or distressing experiences could have a lasting impact on health-
care professionals, and leave them keen to avoid repeats (prompting health-care professionals to make
choices that supported that goal). Memorable (dramatic and usually traumatic) local cases and high-profile
cases from other units/services (e.g. those receiving extensive media coverage because of neonatal
deaths and/or disciplinary action against health-care professionals) appeared to exert a similar hold over
less-experienced clinicians, as the following quotation from a specialist trainee illustrates:
I think that also, because of the Ninewells case50 – you know, with the consultant and the breech delivery,
that was probably about 2 years ago – I think people are also a little bit more mindful, and sort of keen to
go for a caesarean section, because . . . people would feel that there’s less likely a chance of sort of neonatal
morbidity and mortality associated with a section – in the immediate aftermath at any rate . . . It [the
Ninewells case] was a 24-week breech . . . a vaginal breech delivery was attempted . . . and essentially,
unfortunately, baby died – and there was a decapitation.
OB4
Patterning of mode of birth preferences by clinical scenario
Health-care professionals explained that their decisions and practices were dynamic, contingent and
responsive to a wide range of maternal, fetal and service/clinician factors. However, health-care
professionals suggested that presentation (cephalic or breech) and gestational age were particularly
prominent (and intersecting) considerations. Although interviewees articulated a variety of views, some
broad patterns emerged, which are detailed below.
Health-care professionals suggested that cephalic presentations were generally considered lower risk
than non-cephalic presentations. Therefore, a preference for attempting vaginal birth (and avoiding CS),
although not unanimous, was relatively strong and widespread. In support of vaginal birth, interviewees
cited avoidance of short- and long-term maternal morbidities potentially arising from CS; preservation
of women’s reproductive capacity and future birth options; potential benefits to the foetus/baby,
including enhanced respiratory and immune functions; and service considerations, such as meeting
targets to reduce rates of CS.
For some interviewees, however, support for vaginal birth was contingent on gestational age. These
health-care professionals reported that they and/or colleagues would be keenest to undertake vaginal
birth – and feel most discomfort about undertaking CS – at later gestations:
30 weeks onwards . . . babies stand a better chance, they’ll have better outcomes generally . . . And if
they’re a cephalic presentation, and normally grown, and a normal infant, then a normal vaginal delivery
would be preferred.
RM02
The . . . later preterm ones, you know . . . if a baby was head down and it was 34 weeks, I would be quite
reluctant to do a caesarean section . . . Personally . . . I’m not in equipoise at that . . . gestation.
OB8
For cephalic presentations at earlier gestations (i.e. less than 28–32 weeks), preferences for vaginal
birth appeared less stable/strong, with several health-care professionals (including some obstetricians
who reported their usual/default practice as vaginal birth) conceding to some uncertainty regarding
what was actually the best/safest option:
The group that I agonise about are the sub-28 weekers, because those babies . . . are so teeny-tiny and
they’re so fragile, that sometimes you think . . . ‘Does vaginal birth compromise them too much?’
OB8
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Others, although themselves favouring vaginal birth, suggested that colleagues might take a different
view, and explicitly advocate birth by CS at earlier gestations:
There’s a hardcore who already think that every preterm baby before ‘X’ weeks, 32 weeks, should
be sectioned.
OB5
There was greatest consistency in perspective with regard to the most preterm cephalic foetuses (i.e.
22–25 weeks’ gestation). Here, vaginal birth was almost unanimously favoured, with many interviewees
expressing profound unease about conducting CS in this scenario. Obstetricians, midwives and
neonatologists all communicated concerns about the challenges of, and significant maternal morbidity
associated with, the ‘classical’ section typically required:
Perform[ing] a caesarean at 22 weeks . . . is very difficult . . . [and] for future pregnancies it would be
very different than a caesarean section performed later . . . I’m not sure someone would do a caesarean
section at 22 weeks . . . [Possibly] from 24 [weeks], maybe 23-plus, but . . . [it’s] very borderline, because,
you know, you could have a dead baby, so you just get an injury to the mum.
OB11
22-plus weeks, gosh, that’s really, well, less than the age of viability, isn’t it? . . . Why would you section a
woman before 24 weeks? Why would you put a scar on her uterus, for a baby that was less than the age
of viability?
RM02
Indeed, many obstetricians said, categorically, that they would not be prepared to conduct a CS at
what they referred to as the ‘threshold of viability’.
With breech presentations, a preference for birth by CS was more common. Again, strength of feeling
appeared to be affected by gestational age, with preferences for CS being most pronounced at later
gestations (i.e. ≥ 28–32 weeks’ gestation). Accounting for this, health-care professionals highlighted a
variety of concerns about the potential complications of a breech vaginal birth:
With the breeches, where they’re preterm . . . the lower half of the body can slip through a moderately
dilated cervix, but . . . the cervix wouldn’t be large enough for the head to pass through . . . and then it’s
an extremely stressful situation – when you’re at the point of no return and, you know, half of the baby
is out, but the head gets stuck in the cervix, and then attempts have [to] be made to cut the cervix,
with the baby’s head sort of millimetres away.
OB4
Owing to these risks, some interviewees said that they would never, or hardly ever, be happy to deliver
a preterm breech baby vaginally:
A breech itself is risk, and a premature breech then is risk [added] to risk. So I would never be happy
doing a vaginal breech on less than 37 weeks.
OB12
However, although recognising the challenges, around half the interviewed obstetricians said that they,
and/or their colleagues, would at least consider vaginal birth in breech presentations when gestational
age was < 28 weeks:
Many of my colleagues . . . are OK if it’s very early, [although] if they get to kind of 28 weeks and
upwards, or a bit higher than that upwards, they would be less happy about a woman having a vaginal
breech delivery.
OB1
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As with cephalic presentations, obstetrician interviewees reported some uncertainty about the best
way to manage breech presentations at these early (but not extreme) gestations.
Similarly (to cephalic presentations), at the very earliest gestations included in the trial, some
interviewees suggested that they and/or colleagues might be reluctant to perform a CS:
With a breech delivery that was over . . . about 24 weeks, I would say they would do a caesarean section
for that . . . [But] the little tiny ones, I don’t think they would . . . They obviously are thinking that they’re
probably not going to survive anyway – so if they have a difficult breech delivery, it’s not going to make
any difference.
RM03
Interviewees expressed a comparable reluctance to induce labour at these extremely early gestations.
More generally, interviewees viewed elective birth scenarios as problematic in the context of the
proposed trial. They explained that, in effect, this would involve comparing CS with induction. They
considered this fundamentally different from a comparison of CS with spontaneous vaginal birth:
There is an important difference in babies whose birth you’re planning, versus babies whose birth isn’t
planned . . . It feels to me that that’s a bit of a different question, because you’re factoring in [other] things
. . . There are too many other variables, it’s not just, ‘Should this baby be born vaginally?’
OB8
Obstetricians also stressed that the decision to deliver electively, preterm, was never taken lightly,
as the costs of premature birth were profound. Obstetricians explained that typically this would be
contemplated only when a serious threat to maternal or fetal health had been identified. Several
obstetricians emphasised that such situations tended to require urgent intervention and, as such,
would lead them to favour birth by CS. These obstetricians indicated greatest willingness to consider
induction at gestations close(st) to term.
Diverging from preferred mode of birth is more problematic in some scenarios than others
Health-care professionals recognised that, for the proposed trial to be successful, they and their colleagues
would need to be willing to diverge from preferred MoB practices (Box 6). Although some health-care
professionals suggested that, for them personally, commitment to evidence-based practice might act as
something of a counterweight to imperfect personal equipoise, others expressed the view that getting
people to move away from what they considered best/safest care would prove extremely challenging:
You’re going to be trying to get God knows how many DGHs [District General Hospitals] . . . to change
what they see as safe care for the purposes of a research study. That’s not impossible, but . . .
OB6
BOX 6 Health-care professionals’ comments about MoB in different clinical situations
Key points
Health-care professionals recognised that recruiting and randomising to the proposed trial might require
diverging from MoB preferences. These health-care professionals suggested that the trial eligibility criteria
include some scenarios/populations in which this shift was likely to be more difficult than in others.
Interviewees noted that MoB preferences were at their strongest at the extremes of prematurity (i.e. closest
to term and around the ‘threshold of viability’). In addition, health-care professionals often had marked MoB
preferences for breech presentations and these tended to be strongest at gestations approaching term. In
between the extremes (at roughly 26–32 weeks’ gestation) and in cephalic presentations, health-care
professionals appeared to hold less firm and clear-cut preferences for MoB.
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Trial eligible populations viewed as particularly problematic
Health-care professionals suggested that the trial eligibility criteria included some scenarios/populations
in which convincing them and/or their colleagues to change their practice was likely to be more difficult
than in others. They identified several populations/scenarios in which, they suggested, the risk of
health-care professionals engaging in behaviours with clear potential to undermine the trial (discussed
further below) was particularly high. These corresponded with those populations/scenarios in which
MoB preferences were most marked (i.e. the extremes of gestation, breech births and elective birth),
but also included some additional scenarios/groups (e.g. foetal compromise and women perceived
as ‘vulnerable’).
For example, interviewees suggested that they and/or their colleagues would find randomising in
situations when women (of any presentation) were very close to, or furthest from, term problematic:
I will randomise to any trial that people can convince me about equipoise. It’s just that . . . some of your
inclusion/exclusion criteria are a little wide for me and I might not go as far . . . Would I randomise women
at 36 weeks+6 days with a cephalic to caesarean section or vaginal delivery? In my heart, 100% not.
OB5
My suspicion is that some of the obstetricians, at the very lowest gestations, just won’t be willing to do
a caesarean section and so might be unwilling to contemplate randomisation . . . I think some of them
might have the view that the outcome is so poor for those infants, and the risks so large, that . . . it’s
inappropriate to randomise.
N01
For some obstetricians, breech generally was considered problematic, because of the obstetricians’
strong preference for birth by CS:
The main sticking point for me is the breech thing . . . I wouldn’t really randomise [a] woman if knew she
had . . . a premature breech . . . And I think a lot of other clinicians might feel the same.
OB12
Other scenarios in which some obstetricians questioned their own willingness to recruit and randomise
included foetal compromise (e.g. growth-restricted babies):
It would depend if you could show me data that there was a potential benefit for having a vaginal
delivery in these SGA [small for gestation age] IUGR [intrauterine growth restriction] babies . . . some data
to show . . . there’s a definite benefit to having those contractions, to squeeze the fluid out of the lungs,
because it means they’re less likely to have transient tachypnoea.
OB9
It was also suggested that clinicians might also be reluctant to recruit and randomise women they
viewed as emotionally fragile or vulnerable. This might include:
Women who’ve had bad obstetric history, or are really anxious . . . and don’t want any sort of uncertainty.
And prims as well . . . [Women having] first-time babies . . . are likely to be a lot more anxious . . .
[Although] to be fair, everybody ought to have the opportunity to take part . . . so maybe we shouldn’t
make assumptions . . . It’s difficult.’
RM04
Trial eligible populations viewed as less problematic
Conversely, interviewees suggested that where MoB preferences were less marked, they and/or their
colleagues would find recruiting and randomising less problematic. These interviewees suggested
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that this might be the case between the extremes of prematurity (at roughly 26–32 weeks’ gestation).
For example, one neonatologist remarked:
The 25, 26, 27-weekers . . . there is a very real question about how they should be delivered, whether it’s
caesarean section or aiming for vaginal delivery. And . . . I think the obstetricians would find that an easier
population to randomise.
N01
However, for some, this window of possibility was very tightly circumscribed in terms of gestational
range and, for a few, presentation remained a prominent concern (with these interviewees suggesting
that they would still only feel comfortable randomising cephalic presentations). As varying positions were
expressed within interviews, pinning down the boundaries of personal equipoise often proved difficult:
For me, the biggest question is women who come in in spontaneous labour, and particularly the very preterm
but viable infants. So more than 24 weeks – less than 26 . . . 28 weeks . . . 32 weeks would be definite cut-off.
OB08
The presence of such contradictions, corrections and/or qualifications in accounts suggest that, in many
instances, interviewees were (re)formulating and (re)considering the certainty of their convictions as
they talked. Explaining their hesitancies, interviewees highlighted the range of other factors that might,
independently or in conjunction with gestational age and presentation, shift their preferences and
practices around MoB. These included, inter alia, multiple pregnancies, degrees of fetal and maternal
compromise, and other maternal characteristics, such as age and obstetric history. Interviewees
stressed that these considerations were numerous, intersecting and could present in an almost infinite
number of combinations. This, they said, made it ‘very difficult to know at exactly what point are you
going to say, “I’m in equipoise”’ (OB5).
Marked mode of birth preferences are expected to lead to behaviours detrimental to the trial
Interviewees anticipated that the strong MoB preferences described above would prompt actions and
behaviours at both unit/service and individual levels that would present tangible challenges to the
proposed trial (Box 7).
Declining to host the trial
Interviewees emphasised that decisions to host a trial are made by teams rather than individuals and
that their department would only sign up if there was unanimous support:
As a department [you] will have agreed to take part only if . . . you feel you can [all] support that
conversation with women . . . We discuss our individual points of equipoise, and also where we feel there’s
maybe not equipoise. And we’d only take it on if, as a group . . . we were all prepared to sign up for it.
N02
BOX 7 Health-care professionals’ views of the impact of MoB preferences on the conduct of a trial
Key points
Health-care professionals predicted that the existence of marked MoB preferences would induce
behaviours that would potentially compromise the proposed trial. These behaviours included declining to
open the trial, reluctance to recruit and randomise certain patients, directive counselling and/or deviation
from protocol post randomisation.
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Echoing this suggestion, and based on conversations with obstetrician colleagues about the proposed
trial, some research midwives (based in less research-active centres) expressed deep reservations that
it would be possible to open the proposed trial at their centre:
We wouldn’t be able to agree to open this trial here because there would be no point . . . Equipoise is




Health-care professionals often observed that, although they and/or their colleagues might make a
general commitment to the trial, they/their colleagues might be reluctant (or even refuse) to recruit in
those scenarios or populations in which practice preferences were strongest:
Something that you would have to allow for in the . . . protocol, is that, you know, some units may say,
‘Well, absolutely we’re not doing that at that gestation, but we’re prepared to do it at a lower gestation’,
and vice versa. You may get some units that absolutely categorically refuse to section a 23-week woman,
and others that will.
OB10
Health-care professionals suggested that this reluctance might also lead to more insidious and discreet
selecting of patients clearly meeting trial eligibility criteria:
I think there’d be a lot of things like, ‘Oh well, maybe we shouldn’t include this person . . . I don’t think we
should do a caesarean on them, so I don’t think we should randomise them’.
RM02
Counselling discouraging enrolment
Several obstetricians suggested that reservations about one MoB (either vaginal birth or CS) might
also lead health-care professionals to counsel patients in less than impartial ways. These obstetricians
warned that subtle modifications to recruitment conversations could significantly affect their outcome:
I would say . . . ‘We’ve got this trial . . . to see whether it’s safer to do caesarean or vaginal delivery . . .
if you’re not on the trial, our general approach is to go for a normal [vaginal] delivery’. Now, If I don’t
add that last bit, I . . . end up in an argument, ‘Well, you’re not going into the trial, but actually we’re
not offering you [a] caesarean . . .’ So how you counsel people is never unbiased. Some people talk about
non-directed counselling – it doesn’t exist!
OB5
Deviating from the protocol post randomisation
Finally, obstetricians warned of how discomfort with the practice(s) required by the protocol might
result in deviations, in particular to health-care professionals defaulting to their preferred MoB
post randomisation:
I think there will be protocol deviations. So, I think that if someone is randomised for section, they’ll get a
section, no probs. I think if people are randomised to vaginal delivery, on that arm you’ll see more protocol
deviations . . . documented as ‘Clinical reasons: decided caesarean section more safe’. Just because it’s so
much easier.
OB4
Recognising that such behaviours have consequences Health-care professionals further noted how
the above practices and deviations could have profound implications, including difficulties achieving
recruitment targets and the final sample being skewed towards less problematic/controversial
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gestational ages and/or presentations. This, interviewees further warned, could result in findings that
were open to challenge (with regard to their certainty and generalisability) and that could, therefore,
ultimately be disregarded by health-care professionals who were disinclined to modify their preferred,
habitual practices.
Aim 2a: explore if (and what) aspects of the trial design would need to change to
make it more acceptable to health-care professionals
Modifying the trial protocol
Interviewees suggested that the chances of successfully delivering the trial would be increased by
modifying the protocol, critically, by excluding those scenarios/populations in which MoB preferences
were particularly marked (Box 8). Even those who personally viewed the proposed inclusion/exclusion
criteria as ‘perfectly appropriate’ recognised that many colleagues would find them problematic.
These individuals suggested that, as currently conceived, the trial would ‘bump into what is perceived
reality on the shop floor’ (OB6). Different interviewees proposed excluding different scenarios/groups,
including the extremes of prematurity, foetal compromise/anomaly, multiple pregnancies and elective
deliveries. Excluding the first of these groups [i.e. babies furthest from and/or closest to term (both
cephalic and breech)] received the most consistent attention:
I would bring up the lower limit gestation . . . bring the lower limit to 24 weeks . . . Including those
22, 23-week gestation babies . . . involves an area of pretty experimental medicine really. And then . . .
presentation in the bigger babies . . . maybe bring your upper limit down to 34, rather than going all the
way up to 36+6 – because I . . . accept that you’re going to put preterm breech babies in there, because
that’s what you want to look at really, as much as the cephalic ones . . . but you’ve also got to balance
that against the risk of the baby getting stuck.
N03
Ensuring that health-care professionals have confidence in the trial design
Interviewees emphasised that the trial needed to be highly robust in its design and scaled to ensure
that it could deliver definitive answers. Reflecting on previous trials’ failures to deliver the clear-cut
findings needed to bring about changes in practice, some interviewees suggested that pivotal design
features, including the proposed (sub)sample sizes and outcome measures, warranted further thought.
(Sub)sample sizes
Although some interviewees welcomed the breadth/diversity of the study population, many questioned
if – and what – subgroup analyses should be planned, and if sufficiently large subsamples would be
achieved to support those analyses. These interviewees suggested that (perceived) weaknesses of this
BOX 8 Health-care professionals’ comments on strategies to make trial design acceptable
Key points
Some health-care professionals suggested that it might be necessary to change the trial design to make it
widely acceptable. These health-care professionals noted that where MoB preferences were most marked,
and support for the trial particularly weak/compromised, modifying trial inclusion/exclusion criteria might
make it more acceptable. Interviewees emphasised that health-care professionals would also need to have
full confidence in other aspects of trial design and suggested some further areas for attention and
improvement. In addition, some health-care professionals felt that support for the trial might be improved
by raising awareness of the (need for) evidence.
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sort might undermine both health-care professionals’ support for (delivery of) the trial and, ultimately,
their willingness to accept and act on its findings:
They’re going to have a real mixed bag of women, and different indications . . . it’s so diverse that as a
practicing obstetrician, [whether] you would have enough confidence in its . . . power for these different
groups . . . . I’m not sure.
OB01
I’m worried that you’re going to recruit such a . . . heterogeneous group . . . 20 of these, 40 of those, a 100
of those. And you won’t be able to do any subgroup analysis that’s of any meaning.
OB05
Outcome measures
Interviewees emphasised that the value of the trial hinged on collecting the right data on fetal/neonatal
and maternal outcomes. The interviewees stressed that, for clear conclusions about the relative effects
of the two MoB to be drawn, outcome measures needed to be capable of identifying relevant differences.
Reflecting on the primary neonatal outcome (i.e. composite of alive at 6 months after birth or to home
discharge, without significant IVH or cystic periventricular leukomalacia), some interviewees questioned if
the frequency of these events was sufficient, especially at later gestations, to differentiate the outcomes
of the two MoBs:
[In] that cohort of more-than-32-week infants, the chance of significant IVH is very small. [So] if the aim
of caesarean delivery versus vaginal delivery is to avoid that, then it seems that the number needed . . .
would be very high . . . that sort of outcome would be very difficult to study in a randomised trial.
N01
In addition, some neonatologists questioned if, and how, these measures were related to MoB:
I guess if . . . it [CS] was going to reduce the incidents of IVH or cystic periventricular leukomalacia, that
would be . . . a very, very good outcome . . . [but] I’m struggling to think of a mechanism by which that
would happen. Because in my experience, IVH, whilst you can get them fairly early on, often it’s not until
after they’re born . . . And cystic PVL [periventricular leukomalacia] . . . [also] tends to be something that
comes up later, and usually there’s been something to explain it . . . some kind of post-delivery insult . . .
I’ve never really had a feeling that . . . they’re related to the way they were born.
N04
Many interviewees emphasised that what was important to parents, perhaps even more so than clinicians,
was how babies/children developed over subsequent months and years. These interviewees noted that
measures such as IVH and cystic periventricular leukomalacia were essentially proxies for such outcomes:
As neonatologists we are often thinking that what matters most is the outcome of the child in later
childhood, and conscious that when you look at surrogate markers like IVH, although it’s clearly important,
that occasionally the later outcome doesn’t agree . . . If this were designed as a neonatal trial, rather than an
obstetric trial, I suspect the primary outcome would be neurodevelopment, rather than survival or IVH.
N01
These interviewees said that, ideally, these longer-term developmental outcomes should be measured
directly. A few (obstetricians) suggested that capturing longer-term maternal outcomes was important, too:
If your primary outcome measure is fetal handicap [and] survival . . . that’s fine . . . [but] the problem is
the longer-term outcome. So like the problems of increasing caesarean section rates . . . 15–20 years [on]
people get menstrual disturbance . . . there’s a much higher rate of placenta praevia and accreta, but
that’s a consequence in 3, 5, 10 years’ time – studies don’t look at that.
OB05
DOI: 10.3310/hta25610 Health Technology Assessment 2021 Vol. 25 No. 61
Copyright © 2021 Norman et al. This work was produced by Norman et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
61
However, this lack of longer-term outcome measures was also acknowledged as being a weakness
common to many (obstetrics) trials, and reflective of the restricted nature of much research funding.
Raising awareness about the (need for) evidence
Although our interviewees portrayed themselves as cognisant of the need for evidence, some questioned
whether or not health-care professionals more widely were aware of the limitations of the evidence, with
one midwife, for example, describing her colleagues as ‘very shocked’ to hear that there was minimal
evidence to support current practice(s). Therefore, some health-care professionals surmised that a starting
point in securing health-care professionals’ support for the trial would have to be raising awareness of the
current state of the evidence base. Obstetricians emphasised that those clinical scenarios in which MoB
preferences were especially marked (e.g. at the extremes of gestation) would need particular, focused
attention. Theses obstetricians suggested that, in so doing, it would be critical to have credible advocates/
champions making the case for the trial:
. . . a prominent face . . . a big name.
OB4
Others emphasised the importance of identifying and getting the support of local decision-makers and
opinion leaders:
People will follow the lead . . . follow the local academic lead . . . So long as it’s not perceived as blatantly
unsafe, then they will follow that lead and randomise.
OB10
Aim 3: determine if there are any practical, logistical or other challenges likely to
impede trial delivery, and establish what resourcing and other support health-care
professionals might need to overcome these
Concerns about the sufficiency of clinical and research resources
Interviewees drew attention to workload issues that might impair their own, or their colleagues’ at
other (smaller) centres, capacity to contribute to the trial (Box 9):
It’s time, isn’t it? It’s like ‘busy-busy’!
RM03
Interviewees emphasised that, as well as having an impact on the workload of obstetricians, midwives
and labour ward staff, MoB decisions had implications for anaesthetists’ time, theatre usage and labour
ward bed occupancy. Interviewees noted how, with more work to do than time to do it in, health-care
professionals might, quite reasonably, prioritise other tasks:
A challenge with any clinical trial, [is] getting people to take part in research when they’re already very
busy with their clinical jobs . . . although everybody’s aware of research, you know, it can sometimes just
be seen as a bit of a nuisance on top of your . . . busy NHS job.
OB3
BOX 9 Pragmatic issues that might make delivery of a trial challenging
Key points
Interviewees also highlighted more pragmatic issues that might make trial delivery challenging. These
related, principally, to (1) service and research resources and (2) health-care professionals’ clinical and
research skills. Interviewees suggested that – in some units/services – significant support (investment and
training) would be needed to make a future trial feasible.
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Many (obstetricians) expressed the view that recruitment would need to be ‘clinician led’, as
discussions about MoB require clinician expertise. However, these interviewees also acknowledged
that they would need the help of research support staff, including Good Clinical Practice (GCP)-trained
research midwives, in identifying, screening and randomising eligible patients:
Even if the clinician took consent, they’d often need a little bit of support with the randomisation process,
and that can be not just inexperience of doing it, but also just workload. And, therefore, when you’ve got
. . . research support staff . . . you get better recruitment.
OB7
Interviewees noted how patients could present 24/7, with some commenting that research midwives
worked largely office hours. Therefore, even at those sites with more developed research infrastructure
and support, interviewees envisaged challenges recruiting and randomising out of hours. It was noted
that a large group of (clinical) staff would need to be willing and able to provide support to the study if
eligible patients were not to be missed. As interviewees further noted, these people would need GCP
certification and also, some suggested, some trial-specific training, as well as a proportionate amount of
ring-fenced time:
Centres that become involved in a study like this have to really commit to it, and have a number of individuals
who are very dedicated to it . . . And you probably need to have a certain amount of dedicated resource.
I don’t think it’s enough . . . to simply expect people to take it on as part of their day-to-day workload.
N05
Concerns about the adequacy of (some) health-care professionals’ clinical skills
Interviewees questioned how many units/services could guarantee the availability of staff with the
necessary skills to deliver both arms of the proposed trial effectively. Obstetricians emphasised the
criticality of this issue in the more challenging birth scenarios encompassed by the trial (e.g. breech
vaginal birth or very early CS):
These extreme preterm gestations, you can’t just leave it to the registrar, the junior registrar, to do these
deliveries. These are deliveries that need input from experienced people.
OB9
Several interviewees, although emphasising that their own (large, tertiary) service had 24-hour
consultant cover [‘There’s always two obstetricians on-call’ (OB11)], warned that this was not the case
at other centres. Interviewees surmised that the availability of staff with appropriate clinical skills
and confidence would have implications for both recruitment and study outcomes. Therefore, some
interviewees suggested that the trial team should focus on tertiary units where there was greater
experience of both difficult vaginal births and CSs and 24-hour consultant cover:
My unit has 24 hours – they can sort of cover – so it makes no difference really what time of the day or night
it happens . . . that wouldn’t affect it. But I guess if you’re trying to randomise in other units it would, and that’s
potentially a problem . . . I think you probably wouldn’t want to do this . . . in units where there isn’t experienced
obstetric cover available for breech vaginal delivery – because that’s necessarily going to bias your results.
OB10
Although some interviewees surmised that in the bigger clinical units appropriate skills and confidence
could be assumed, others suggested that for some clinical scenarios, in particular breech vaginal birth,
even ‘experienced’ clinicians might vary in their skills and confidence. Health-care professionals drew
attention to a general shift away from vaginal breech birth following the completion of the Term Breech
trial.13 Some interviewees remarked that, as a consequence of that trial, there had been limited/diminishing
opportunities for junior doctors to acquire and embed the necessary skills and confidence to deliver babies
this way. Although many interviewees saw this as a major stumbling block for the trial, some suggested
that investment in skill development and support might increase the pool of health-care professionals
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(i.e. obstetricians) with the skills and confidence necessary to undertake these more complex vaginal births
successfully. Proposals included offering ‘a refresher course about vaginal breech’ (OB4) and ensuring that
less-experienced obstetricians had ‘some senior support’ (OB12) when undertaking this MoB.
Some interviewees additionally emphasised that birth by CS could also be difficult. These interviewees noted,
in particular, that very early CS, especially ‘classical caesareans’ involving a long vertical incision, presented
significant technical challenges, again, warranting the involvement of a senior, experienced obstetrician.
Some interviewees opined that the profession lacked experience and the necessary technical expertise
to successfully undertake CS at the earliest gestations covered by the trial (i.e. 22–24 weeks’ gestation):
I’d expect a caesarean section to be more difficult [at 22–24 weeks], so there is a technical issue here.
We’re not really expert in doing a caesarean at these gestational ages.
OB11
Concerns about the adequacy of (some) health-care professionals’ research skills
Alongside identifying gaps in clinical skills, interviewees questioned whether or not they and/or colleagues
had the necessary research skills. In particular, concerns related to the challenges of securing informed
consent intrapartum. Health-care professionals expected these conversations to be complex and
challenging, especially when PTB was entirely unexpected:
Women in high-risk groups . . . they’re an easy-ish group to speak to because they have prior knowledge
and prior experience . . . and they’re out with the kind of labour scenario. Now the challenge is . . . a lot of
the women that come in in preterm labour are just coming in in preterm labour . . . Speaking to somebody
who’s in labour is harder.
OB1
Many interviewees expressed personal discomfort about broaching trial participation with women who
were in active preterm labour. Others interviewees said that they expected colleagues to have concerns
and some anticipated significant reluctance to be involved:
No-one will want to do the study, with the exception of weirdos like me! Every single R&I [Research &
Innovation] midwife and nurse is going to try to not consent women for us . . . because it’s an
uncomfortable conversation.
OB6
Intrapartum recruitment (to any trial) was perceived as presenting distinct practical and ethical challenges.
Several health-care professionals expressed uncertainty about women’s capacity for decision-making
in the light of pain, analgesia and – in the context of PTB – (di)stress. Some health-care professionals
questioned if, under these conditions, informed consent was achievable:
A caesarean in one pregnancy . . . restricts your options for the next pregnancy. But that’s a difficult
decision for women to make when they’re not in labour and they’re not worried about having a preterm
baby . . . Asking them to do that when they’ve got all that going on . . . I would not be entirely happy . . ..
I think it’ll be very difficult for a woman and her partner to give truly informed consent under
those circumstances.
OB1
The need to ensure that women were aware of the potentially serious and enduring consequences
of the two MoBs was viewed as compounding the difficulty of the conversations that health-care
professionals needed to have:
That would be a really difficult thing to consent women for . . . it would be a massive conversation.
M01
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Health-care professionals’ comfort with the idea of seeking informed consent intrapartum appeared
to be related to the extent of their prior experience of intra- and peripartum trials. Those health-care
professionals with more experience reported feeling more comfortable with the idea. A few interviewees
suggested that training and tools might help less experienced health-care professionals feel more at ease
undertaking this work. Some health-care professionals went further, arguing that training around consent
would be essential:
[Clinicians] need a lot of prep[aration] about the consent process . . . a lot of support through that discussion,
and a lot of case scenarios, and a lot of working out how you can take informed consent in different
situations in an intrapartum setting.
OB7
Refining the consent process
Health-care professionals also proposed some refinements to the trial consent process. Many health-care
professionals were in favour of introducing the trial to women earlier in their pregnancy (i.e. before they
went into labour) and some opined that this could provide a basis for – and, indeed, should be a condition
of – the securing of verbal consent intrapartum:
Having an option for verbal consent is a good idea . . . having the written consent afterwards . . .
[But] I think you’d have to have quite a good way of informing women about the trial [ahead of time] . . .
Because with verbal consent, I don’t think the . . . time they can give verbal consent is the first time
they’ve ever heard about the trial, within the consent guidelines that we’ve worked within.
OB07
Several health-care professionals suggested making all women aware of the trial by mentioning it and/or
distributing leaflets at key appointments (e.g. at the 20-week scan). Some health-care professionals noted
that an alternative, more targeted, approach would be to make women identified as at risk of PTB, who
were often seen in specialist clinics, aware of the trial at their appointments. However, interviewees
noted that publicising the study – even in the latter, more targeted way – would result in many women
who ultimately gave birth at term receiving information. This, they said, could have costs for both
health-care professionals and patients, creating work for the former and, potentially, unnecessary
anxiety for the latter:
If you introduce the possibility of preterm labour early on in pregnancy, you’re . . . potentially worrying,
or raising concerns in, a lot of women who will not go on to deliver preterm.
N05
Aim 4: understand and explore the potentially distinctive challenges of recruiting
ethnic minority women into the trial, and establish any additional resourcing and
support needed to optimise these women’s participation
The complex trial design we were tasked with unpicking with health-care professionals left limited
time in interviews to explore their perspectives on the challenges of recruiting ethnic minority women.
Consequently, we captured only a small number of data on this topic.
Health-care professionals emphasised the diversity of the populations they served and described
anticipating particular difficulties recruiting ethnic minority women into the proposed trial:
My personal . . . experience . . . was that it’s . . . much more difficult to recruit, you know, all ethnicities that
are not white European to medical trials . . . so even similar, sort of British-born but ethnically not white
people . . . Patients are often extremely well motivated, and very altruistic . . . but my personal finding has
been that it’s more difficult to get consent from non-whites, non-white European ethnic groups.
OB4
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Different cultural frameworks and expectations (regarding health care, birth/labour and research) were
suggested as potentially affecting women’s responses to trial invitations:
Also, yeah, cultural – cultural implications would be really interesting. So, for example, lots of women who
have come from kind of Africa, they kind of just get on with it . . . just keep going – ‘What will be will be’.
And obviously you’ve got all the family influence . . . the cultural influence, you know, the religious influence . . .
all of that is definitely relevant . . . and I think would affect people’s opinions of being part of the trial.
M01
Profound difficulties were anticipated when women did not speak English as their first language, and
the support of interpreters was required. Challenges identified by health-care professionals included
getting hold of a suitable interpreter when the need for one had not been anticipated and ensuring the
integrity of information relayed through a third party:
It’s an extra barrier . . . if they don’t speak English they certainly won’t read English . . . [and] they may not
even be able to read their language either . . . if we’re approaching them in clinic, or something that’s been
booked, then an interpreter is usually there, but it’s a bit more difficult if they turn up unannounced.
RM04
We’d have to use interpreters, which would be interesting as well. So that adds another level of bias . . .
I’m sure they [interpreters] will have an opinion about it.
M01
These potential language barriers compounded health-care professionals’ anxieties about the feasibility of
securing informed consent. Similar concerns were expressed by women taking part in the FGs (see Part 2:
findings from the focus groups with women).
Part 2: findings from the focus groups with women
Although (as discussed previously) we did not achieve data saturation in this element of our study,
some issues were prominent in the discussions. These issues warrant reporting, as they indicate
potentially important concerns about trial participation.
Achieved sample: pilot group/focus group participants
The characteristics of our achieved sample of women are detailed in Table 8. Individual/quoted pilot
and FG participants are not characterised, as this sort of information might compromise their anonymity.
Aim 1b: determining whether or not women would be willing to participate
in the trial
‘A big decision’ with risk of allocation to unnecessary surgery
Focus group participants highlighted the significant and very different short- and long-term
implications of the two MoBs investigated in the trial. In particular, participants raised concerns about
the potential for trial participation/randomisation to result in a woman having unnecessary and
invasive surgery. Participants also expressed scepticism about women’s willingness to accept
randomisation to CS, in the absence of a decisive medical indication for such a procedure (Box 10):
I would be worried that they would assign me to a C-section, although there might not be health
indications towards this. I would prefer to give birth naturally.
FG 2/P3
Why would you opt for major surgery, unless you really had to have it?
FG 1/P2
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BOX 10 Determining whether or not women would be willing to participate in the trial
Key points
Across the groups, participants highlighted some issues and concerns that might potentially affect women’s
willingness to take part in the proposed trial. These concerns are encapsulated in the following quotations/
phrases: ‘a big decision’ (FG 1/P4), a bad time and ‘the doctor (still) has their part to play’ (FG 2/P1).
TABLE 8 Characteristics of PG/FG participants (n = 13)
Characteristic Number of participants
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These women highlighted the surgical risks of CS (e.g. bleeding and infection), lengthy recovery times,
impact on one’s ability to provide care for the new baby (and any other children) and implications
for future pregnancies/births. These women noted how these possibilities might lead them to favour a
vaginal birth:
I might have an inclination to want to have a vaginal birth, just because if you have a C-section, you’re
more likely to have to have a C-section the second time round.
PG/P2
Having had a C-section, if I could have had a normal delivery, normal vaginal delivery . . . I think I would
have taken that over the C-section any day, because I wouldn’t have had a major operation, I wouldn’t
have had 6-plus weeks of recovery, you know?
FG 1/P3
However, as the second of the two quotations above suggests, views on the desirability or otherwise
of the two MoBs were shaped by women’s prior experiences. Indeed, those who had experienced
complications during, or because of, vaginal birth emphasised that this MoB too could have serious
and burdensome implications:
I had a third-degree tear and other issues, so literally as soon as I had him, I was off in surgery anyway . . .
and that was with a vaginal birth.
FG 1/P1
I’ve had both a natural birth and a C-section and I’m not really sure what is worse – as I had forceps
delivery, which was not fun at all, I had a cut, and they stitched it badly.
FG 2/P4
Women without prior experience of childbirth appeared not to have (such marked) MoB preferences.
Nevertheless, they still viewed the decision as a significant one.
A bad time: discomfort with intrapartum consent
Women in all groups found the idea of being approached and consented in the intrapartum period
deeply problematic:
If she’s in labour, obviously her waters have broken, she’s panicked and she’s being told to make a
decision. . . It’s quite a big decision . . . to be introduced to it at that point!
FG 1/P4
It’s . . . about timing, and being able to think straight . . . you have to be in the right frame of mind to
make important decisions.
PG/P2
Those who had experienced a spontaneous PTB highlighted how ill-prepared they had been for the
premature onset of labour. Moreover, FG participants who had previously given birth emphasised how
labour more generally affected women’s ability to concentrate, highlighting the effects of shock, pain,
medication and a narrowed focus on ensuring optimal foetal outcomes:
During labour a person stops thinking and focuses only on this eventually ending, on the child being
healthy, on themselves being well . . . This is what I think every mother thinks during labour.
FG 2/P3
QUALITATIVE RESEARCH
NIHR Journals Library www.journalslibrary.nihr.ac.uk
68
Having ‘so many more important things going through our minds’ (PG/P2) might, as FG participants
suggested, make women unreceptive to approaches about trial participation:
It is just the last thing on your mind, it’s absolutely the last thing.
FG 1/P3
Here I am, about to give birth, I’m in pain all over, I’m worried . . . and someone approaches me and asks
about some research study. First thought? ‘Damn, just piss off! I don’t give a damn about your research
just now, I just want to make sure that all is well with my child’.
FG 2/P4
Other women noted the potential challenges of securing genuinely informed consent. To illustrate this
point, a FG participant who had previously had an emergency CS questioned if the consent she had
given could really be considered informed:
I was asked to sign loads of consent forms and I don’t even have a clue what half of them were, because
someone was just telling me, ‘You need to sign this in order to get the babies out, to give them a chance
to live’, and I’m like, ‘Fine – I’ll sign whatever it takes!’
PG/P2
In the light of these concerns, women in all groups favoured introducing the trial earlier in pregnancy
(somewhere between 9 and 20 weeks):
If someone had mentioned something beforehand, so you were aware . . . [of] this possibility.
FG 1/P1
I think planting a seed earlier on, giving some literature or a leaflet to say, ‘Look, this is a study that’s
happening. It’s not to say that you’re going to have a preterm birth, but it’s an interesting read. Have a
think about it’.
PG/P1
Reflecting further, some women suggested inviting women to indicate interest in trial participation in
their birth plans:
She could include this in her birth planner, whether she would like to agree to such a thing . . . It’s obvious
that things do not go according to plan every time, but . . . midwives always try to consider the birth plan
the woman has with her.
FG 2/P2
Although some participants drew attention to the potential of early information to induce unnecessary
anxiety in women who would ultimately deliver at term, others felt that, if information was composed
and provided in careful and sensitive ways, this could be avoided. Moreover, some participants were
strongly in favour of raising awareness of, and preparing women for, the possibility of PTB, and surmised
that trial information might help achieve this:
That would be good, to raise awareness among those who could potentially – just generally, among all
mothers, as you don’t know who . . . might have a preterm birth – that there is such an option, and that
something like this might happen . . . [Then] they are able to prepare themselves for this emotionally.
FG 2/P2
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‘The doctor (still) has their part to play’: relying on health-care professionals to safeguard
women’s interests
Focus group participants emphasised that health-care professionals remained an important part of the
equation and women’s agreement to enrol in the potential trial did not – or should not – relieve health-care
professionals of responsibility to consider and safeguard their interests. To the contrary, women expected
health-care professionals to assess individual women’s suitability very carefully and consider whether or
not, in the light of factors specific to that individual, they could truly claim to be in equipoise:
I think it’s important that the doctor is considering what the safest option is, and you’re only having the
random choice made by the computer as long as there’s nothing else . . . no other factor that would be
important to consider.
PG/P2
Participants highlighted how the clinical (and social) circumstances of PTB were highly variable and
stressed that women wanted and expected to be treated as individuals, and counselled accordingly.
Although participants did not necessarily see this a barrier to trial participation, they stressed that the
information given to women about trial participation and the pros and cons of the two MoBs should
be tailored to their particular circumstances. For example, FG 2 participants suggested that women’s
perspectives and concerns might be quite different across the gestational age range covered by the
trial and PG members suggested that health-care professionals should give women detailed information
about the respective risks and benefits of the two MoBs at the gestation they were at. The PG members
noted, for example, that there were different ways of performing a CS and that the type of incision made
would be influenced by individual factors, including the size of the uterus and whether it was a singleton
or twin pregnancy:
They could . . . say, ‘Well, these are the risks associated with us doing an incision this way, as opposed to
that way, because the baby is extremely premature’.
PG/P1
Health-care professionals also had views on women’s willingness to participate, as described in Box 11.
Aim 4: to understand and explore the potentially distinctive challenges of recruiting
ethnic minority women into the trial, and establish any additional resourcing and
support needed to optimise these women’s participation
Family and autonomy
Women from the three groups reflected on ownership of, and influences over, decisions about MoB
and participation in the hypothetical trial. Women in the PG and in FG 1 (all of Indian ethnicity) mostly
framed the decision as one they would make jointly with their husband/partner, with some questioning
whether or not women could make such a decision independently. The potential for women and their
husbands/partners to have different priorities, and for different opinions, therefore, to emerge, was
noted by members of FG 1 (Box 12). One woman questioned what might happen should there be a
marked difference of opinion between a woman and her husband/partner:
There could be a conflict of what happens, because there’s an emotional side and a physical side . . .
If it’s a conflict, then what happens in that situation? Because the baby’s joint. Just because the woman’s
delivering it, the responsibility is on both.
FG 1/P4
Another FG 1 participant commented that every relationship was different, and warned that not all were
supportive/healthy. Therefore, she surmised, discussions about MoB and trial participation should, in the
first instance, ‘be had privately with [women]. I mean, ultimately there’s a confidentiality issue’ (FG 1/P3).
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Participants in the PG and in FG 1 further noted how the lives of women of Indian heritage might
be closely entwined with those of their extended families. Some participants explained that they
lived with their husband’s family (e.g. their mother- and father-in-law). Those who lived independently
BOX 12 Challenges of recruiting particular groups of women
Key points
The three groups highlighted different potential challenges to recruiting ethnic minority women: family and
autonomy (discussed by the PG, FG 1 and more fleetingly by FG 2), language and consent (discussed by
FG 1) and expectations of health care (discussed by FG 2). Women across the groups highlighted the
difficulties/limitations of generalising about the experiences, outlook and needs of women who might
have a shared/common heritage, but very diverse experiences and circumstances.
BOX 11 Health-care professionals’ perspectives on women’s willingness to participate
In the light of the limitations of our FG data, we also report the perspectives of interviewed health-care
professionals. These were quite variable. Some health-care professionals, for example, were optimistic,
and suggested that trial enrolment might offer women a rational way of dealing with uncertainty and the
difficulties for decision-making that creates. A few health-care professionals noted how the prospect and/or
experience of risk, and loss, could act as incentives for women to support research:
If women realise that they’re high risk for something, often then women are keen to do trials and get a better
understanding of what could be the best care.
OB12
However, others, in particular midwife interviewees, offered a more sceptical view, and noted how
some women – like themselves – had strong MoB preferences that might act as barriers to recruitment.
These interviewees also surmised that women might be resistant to having their care determined through
a randomisation process and, instead, look to the care team for more individualised care:
I don’t think it will be positively received by women, because I think they’ll want to know from us which is the
safest option, they won’t want to be randomised.
M02
Where health-care professional interviewees were very much in agreement was that women wanted
‘what was best for the baby’ (RM01) and would prioritise their unborn child’s well-being over both risks
to themselves and potential benefits to others. It was noted that women would, therefore, need strong
reassurance that the risks to the baby of the two MoBs were comparable:
Everybody’s an individual . . . [with] different experiences and pasts . . . there may be some women who
particularly want to do things one way or another, but I think the majority of women, their number one priority . . .
will be the safety of their baby, whatever is best for them . . . [So] in terms of the study, you’d have to be able to
reassure them that neither one way nor the other would increase the risk for the baby . . . you’re just back to the
usual risks and benefits of section, essentially . . . And [that] will just vary from case to case as well, depending on
the reason for needing delivery.
RM04
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observed that their ‘almost westernised’ living arrangements were perhaps ‘not the usual Indian
thing’ (PG/P1).
Women in these two groups noted that extended family could be an important source of support, but
also (potentially) a cause of unhelpful interference and stress. In the case of decision-making about trial
participation, some women surmised that older family members would be against this and, given the
opportunity, might express their views strongly:
I live with my in-laws. They’re quite old-fashioned, so anything like this, they’d be like, ‘No, you’re not
going to – don’t take part!’
FG 1/P3
However, others remarked that, in their case, these family members were/had been medical professionals
and might, therefore, be quite supportive. Some PG participants suggested that although the perspectives
of people other than their husband/partner might have little influence on the decision they made, the
airing of opinions might nevertheless make that decision harder to live with. For this (and other reasons),
these women said that they might limit the information they shared with their extended family.
Language and consent
Focus group 1 considered the issue of language and the implications of this for consent. Although all
group members were professionals who spoke English as their first language, they noted that language
might present a barrier to participation for some other women with Indian backgrounds. These group
members warned that these women might be unclear as to what they were being asked to do, but feel
‘embarrassed to say that [they] don’t understand’ (FG 1/P2). This lack of understanding, they suggested,
might discourage participation and lead to a less diverse sample than the triallists had hoped for. In addition,
the group members emphasised that unresolved language barriers could have significant implications for
the quality of women’s consent and raised serious doubts as to whether or not consent could, in such
situations, be considered ‘informed’. Therefore, the group members suggested that, when English was not a
woman’s first language, the involvement of an interpreter was absolutely key:
You need to have a translator explain everything, even if you think they understand, . . . because . . . it’s a
big decision and . . . it’s important that they are actually fully informed.
FG 1/P2
Expectations of health care
Women in FG 2, all of whom were first-generation arrivals from Poland, reflected at length on the
differences between reproductive and maternity health care in Poland and the UK. Theses women’s
accounts suggested that experience of other health-care systems might create different expectations
of UK health-care professionals and health care, as well as affecting perceptions of the desirability, or
otherwise, of specific medical procedures, with these issues potentially having implications for decisions
about participation in an intrapartum trial.
These women emphasised how pregnant women in Poland were monitored very closely, from
conception onwards, and contrasted this approach with practices in Scotland/the UK:
[Here] until the 12th week, the pregnancy is not considered a pregnancy . . . they simply don’t
support pregnancies prior to the 12th week . . . [whereas] in Poland they do everything to fight for
these babies.
FG 2/P2
Another thing I’ve noticed here . . . is the attitude towards pregnant women . . . In Poland you have
ultrasound scans done very frequently . . . they test your glucose levels . . . there’s loads of checks.
FG 2/P3
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Women suggested that (what they perceived as) the more hands-off approach that is usual in Scotland/the
UK could create unease among a community of women accustomed to, and/or expectant of, closer and
more attentive care. Some women reported that this had prompted them to consult a Polish health-care
professional privately, with one woman warning others that this had, however, led to further worries (because
of the conflicting medical opinions that emerged on the appropriate management of their pregnancy).
Women noted how differences in care/management practices continued up to and, indeed, beyond birth,
with several group members suggesting that there was a reluctance to admit pregnant women to hospital
in Scotland/the UK until labour was quite advanced. Once admitted, some women felt that their choices
were limited, with one woman asserting that ‘[i]n this country . . . there is an extreme pressure to give birth
naturally’ (FG 2/P2). Women suggested that this included scenarios in which (in Poland) a CS would be
considered the more appropriate option. For example, women noted how assisted/instrumental deliveries
considered outdated and, indeed, ‘dangerous’ in Poland remained relatively common in the UK:
In Poland . . . forceps are not used any more . . . this practice has stopped many years ago.
FG 2/P4
With regard to how these (unmet) expectations of care and perceptions of good management/birth
practices might affect decisions about trial participation, women suggested that they might fuel an
innate (national) anxiety:
In my opinion we, Polish women, are anxious.
FG 2/P3
We are anxious, yes.
FG 2/P2
Women further surmised that trial participation might conflict with Polish women’s need to feel ‘in
control of everything’ (FG 2/P3). Moreover, these women’s expectations of close and tailored care
would seem incongruent with the protocol-driven care inherent in a trial and, as such, might plausibly
discourage/disincentivise trial enrolment further.
Discussion
Health-care professionals described the existing evidence base for MoB in PTB as deficient and said
that they would like stronger research evidence to inform future clinical practice. Therefore, health-
care professionals described largely welcoming the idea of the proposed RCT. However, health-care
professionals also anticipated significant challenges to delivering the proposed trial. They explained
that – despite the appearance of clinical equipoise – as individuals they, and/or their colleagues, often
had quite marked and varied MoB preferences. These differences appeared to arise from a variety of
factors, including unit/service norms, personal skills and confidence, direct experience and memorable
local and/or high-profile national cases. Preferences were particularly strong in relation to very
late and very early (preterm) gestations, as well as breech presentations. Health-care professionals
surmised that such preferences would severely affect their and/or their colleagues’ willingness to
recruit and randomise particular groups of women into the proposed trial. Health-care professionals
suggested that awareness-raising activities and, more crucially, protocol modification might increase
health-care professionals’ willingness to recruit. With regard to the latter, the need to tighten the
inclusion criteria and, ideally, review outcome measures was widely highlighted and discussed. Even
with these modifications, other more pragmatic concerns [relating to the (in)adequacy of clinical and
research resources and development of appropriate clinical and research skills] were perceived as
likely to make trial delivery challenging. It was suggested that significant investment would be needed
– in both staff training and broader resourcing and support (e.g. ring-fenced time) – to resolve those
concerns. It was also noted how, to promote the inclusion of ethnic minority women, suitable language
provisioning would be necessary.
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So how do these findings add to what was known already? As noted earlier, previous efforts to conduct
RCTs of MoB in PTB have been unsuccessful, with health-care professionals’ reluctance to recruit/
randomise being suggested as a pivotal factor.3 Our research indicates that this is a plausible assertion
and, moreover, it is one that is likely to present ongoing challenges for triallists keen to resolve the
clinical uncertainties around MoB in PTB, especially if the design outlined in the HTP is used. Critically,
our data offers insights into why, when and to what extent health-care professionals might be reluctant
to recruit. These insights can offer useful guidance moving forward. Specifically, these insights can help
inform decision-making about which inclusion criteria should be retained, and which modified, to make
a trial a more feasible option.
In addition, our enquiries prompted health-care professionals to propose (other) strategies that might
(possibly) encourage and enable more health-care professionals to support and recruit women into a
future trial. These included awareness-raising activities and supporting health-care professionals to
develop appropriate clinical and research-related skills. Clearly, some of these strategies would be
easier and less costly to implement than others. For example, using research champions to raise awareness
is a relatively low-cost option, whereas training/upskilling health-care professionals to perform complex
vaginal births and very early CSs with confidence would be considerably harder, more time-consuming and
expensive. If a trial were to go ahead in the future, the effectiveness of such interventions in promoting
health-care professionals’ engagement might usefully be evaluated in an (inbuilt) pilot phase.
With regard to women’s willingness to participate, our understanding of this issue is best described as
incomplete. Data from health-care professional interviewees suggest that women, like themselves,
may have strong MoB preferences and that these might affect their willingness to take part in a future
trial and accept randomisation. There was some support for these assertions in the FG data. The data
available from the FG also indicates two additional concerns that warrant careful consideration.
The first concern centres on women’s anxieties about undergoing a (potentially) medically unnecessary
and invasive procedure (i.e. a CS) as a result of trial participation. The second concern, which was also
shared by some health-care professionals, involves the challenges and ethics of asking women to consent
to trial participation during labour. This finding is not altogether surprising, as qualitative work undertaken
during a peripartum trial involving women who had a retained placenta likewise highlighted the
challenges of obtaining/giving informed consent in situations in which women are anxious, distracted
and experiencing the effects of analgesics.51 Indeed, like our FG participants, the women who took
part in the retained placenta trial could see clear benefits to trial information being cascaded during
the antenatal period and saw these as outweighing the potential risks/costs of (unnecessary) anxiety
and distress.51 Moreover, early information provisioning aligns with RCOG guidance,52 and other’s
recommendations,53 to promote informed decision-making and valid informed consent. However, this kind
of information/consent pathway has, to the best of our knowledge, not yet been formally evaluated and
careful consideration should be paid to doing this in the event that a future trial goes ahead (e.g. by
conducting qualitative work with women and health-care professionals during an inbuilt pilot phase).
Consideration should also be given to women’s suggestion that they should receive individualised,
rather than generic, information about the trial (i.e. information that is tailored to their specific circumstances,
including gestation). Of course, although general information about the trial could be given earlier in the
antenatal period, it would only be possible to provide tailored information at the point when women
become eligible to participate.
We are hesitant to make claims about the distinctive challenges of recruiting ethnic minority
women to the potential trial on the basis of the data we collected, not least because we did not
have the opportunity to consult white British women and, therefore, to undertake comparative
data analyses. Moreover, different issues emerged in the three groups. Given the range of ethnic
minority communities now living in the UK, considerably more complex and wide-ranging challenges
might be anticipated than we were able to capture. However, a cross-cutting issue, highlighted
by FG participants and health-care professional interviewees, was the challenge of recruiting and
consenting women who do not use/speak English as a first language. Both groups highlighted a
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need for appropriate provisioning (e.g. interpreter services). Such concerns and potential solutions
have also been identified by others, such as Hussain-Gambles et al.54,55 Hussain-Gambles et al.54,55 have
further noted how using professional interpreters and producing written materials (e.g. information
sheets) in a variety of languages can be extremely expensive and this has also been seen as a key
reason why ethnic minority groups continue to be under-represented in clinical trials.55 This is an issue
that the funder may wish to consider if/when commissioning a future (inclusive) trial and deciding on a
funding envelope.
The limitations of our sample of women have already been noted. Our sample of health-care professional
interviewees included people working in a range of roles and maternity settings across the UK, and with
varying levels of experience. The nature of studies, such as our own, however, is that they tend to attract
people with above average interest in either the research topic or research more generally. Our health-
care professional interviewees emphasised their personal commitment to trials/research and, indeed,
many suggested that colleagues at other sites might not share their enthusiasm. Most participating
midwives had research roles/responsibilities and their perspectives may differ from those of exclusively
clinical colleagues. In other words, the health-care professionals who took part in this study might hold
distinctive views, perhaps being more supportive of research generally, but also more ready to critique
the specifics of the HTP in the light of their prior research/trial delivery experiences.
Fundamentally, what our findings suggest is that, were a trial to go ahead, considerable difficulties
recruiting and randomising sufficient patients should be anticipated. Likewise, the risk of trial failure,
due to under-recruitment, should be taken very seriously. The tensions and difficulties revealed by the
research-oriented health-care professionals participating in our study seem likely to be even more
profound among less research-invested peers. Women’s concerns will also need careful consideration
and management.
These findings are summarised in the following section. Chapter 8 then draws together the findings
from the qualitative research with those arising from the survey and Delphi exercise, and presents a
series of recommendations for the funder to consider.
Summary of key findings from the qualitative interviews with
health-care professionals
Support for the idea of a trial involving mode of birth in preterm birth
l There was wide acceptance that the current evidence base regarding optimal MoB in PTB was
deficient, with interviewees highlighting a need for high-quality (RCT) research evidence to
guide practice.
l Interviewees largely agreed that the proposed trial addressed ‘an important question’, but suggested
that running such a trial would present many challenges because of the variation in obstetric
cultures and practices across the UK and a widespread lack of personal equipoise.
l Even with modifications (e.g. changes to inclusion/exclusion criteria), interviewees felt that
recruitment into a future trial would be likely to prove challenging.
Factors likely to impinge on support for the trial
l Interviewees revealed or reported strong preferences regarding MoB in PTB, which they expected
to have an impact on recruitment and protocol adherence.
l MoB preferences appeared to emerge as a result of a variety of factors, including experience, skills
and confidence.
l Some interviewees suggested that skills in managing breech/complex vaginal births had diminished
because of a general move towards intervention by CS.
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Aspects of the trial viewed as particularly challenging
l Interviewees recognised that recruiting and randomising to the proposed trial would involve
obstetricians shifting away from their MoB preferences.
l Interviewees noted that the eligibility criteria for the proposed trial were broad and included some
scenarios/populations in which this shift would be particularly difficult.
l Areas where obstetricians had especially strong MoB preferences and, therefore, might find
recruitment highly challenging included the following.
¢ The extremes of prematurity: at later gestations interviewees strongly favoured the MoB usual
in term births (i.e. vaginal birth for cephalic presentations and CS for breech) and at 22–24 weeks’
gestation interviewees felt that few health-care professionals would be willing to perform CS.
¢ Breech presentation: interviewees reported a widespread preference for birth by CS,
particularly, but not exclusively, at later gestations.
¢ Elective PTB: interviewees suggested that health-care professionals would be more likely to
favour CS when urgent/timely birth was required.
Trial eligibility criteria viewed as less problematic
l Health-care professionals held less firm and clear-cut preferences for MoB between the extremes
of prematurity. However, although interviewees anticipated that they/their colleagues would find
randomising less challenging in such situations, some important differences in opinion emerged with
regard to the composition/boundaries of this ‘less problematic’ group.
¢ Some health-care professionals suggested that they/their colleagues would be comfortable
randomising all women between 26 and 32 weeks’ gestation.
¢ Others suggested that even within this gestational range they/their colleagues would only be
comfortable randomising cephalic presentations.
Other pragmatic concerns likely to further affect support for the trial
l Alongside these concerns about recruiting/randomising (some) women into the trial, interviewees,
especially research midwives, highlighted a variety of other practical factors that might compromise
support for, or local capacity to deliver, the proposed trial. These factors related to the (in)adequacy
of clinical and research resources and skills. Interviewees surmised that substantial investment
might be required to resolve these concerns.
l Health-care professional interviewees – and some women – highlighted the challenges of recruiting
and consenting women who do not use/speak English as a first language. Both groups stressed the
need for appropriate language provision to ensure equity of access and informed consent.
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Chapter 8 Conclusions
Summary of study activities
The overall aim of the CASSAVA project was to determine if a trial to define the optimal mode of PTB
could be carried out and, if so, determine what sort of trial could be conducted and how it could best
be performed. We aimed to determine the specific groups of preterm women and babies for whom
there are uncertainties about the best planned MoB, and if there would be willingness to recruit to,
and participate in, a randomised trial to address some, but not all, of these uncertainties.
Specifically, we aimed to determine which of the four statements below is most accurate, and to define
any uncertainties:
1. There are no uncertainties about the best-planned MoB for any groups of women or babies
presenting in preterm labour.
2. There are uncertainties about the best-planned MoB for specific subgroups of women (which we
will define) presenting in preterm labour, and in the willingness of clinicians to recruit to, and of
women to participate in, a randomised trial to address these uncertainties.
3. There are uncertainties about the best-planned MoB for specific subgroups of women (which we
will define) presenting in preterm labour, and in the willingness of clinicians to recruit to, and of
women to participate in, a randomised trial to address some, but not all of these uncertainties.
4. There is uncertainty about the best-planned MoB for specific subgroups of women (which we will
define) presenting in preterm labour, but women and/or clinical staff are not willing to participate in
a randomised trial to address any of these uncertainties.
We planned a series of clinician and patient surveys and a consensus workshop, using Delphi methods,
to inform the design of a hypothetical clinical trial (HCT). We planned to devise a protocol for the HCT
and a vignette for discussion with potential participants. We planned FGs to talk to participants about
the trial, and telephone interviews to talk to clinicians. Last, we had planned to design and cost a full trial.
We broadly achieved our aims.We conducted clinician and patient surveys and the consensus workshop,
achieving our planned sample size for each. These events were richly informative for the design of a
protocol for a HCT (which we called CASSAVAplus) and a vignette for discussion with potential participants.
We also reached our planned sample size for in-depth interviews with clinicians.
Unfortunately, in March 2020, 5 months into the qualitative part of this study (with FGs with potential
participants and telephone interviews with clinicians), the study sponsor stopped all non-urgent public
health research (including the CASSAVA project) as a result of the COVID-19 pandemic. Face-to-face
FGs were clearly not going to be possible (because of social distancing requirements). In mid-April
2020, we considered virtual (online) FGs. However, consultation through a participant group (the Bliss
Insight and Involvement Group) demonstrated that participants (especially those currently pregnant)
might be experiencing heightened anxiety due to the pandemic, which could potentially be compounded
by research participation. In a face-to-face setting, this anxiety can be somewhat addressed by a skilled
moderator, but this is much more difficult in a virtual setting. Further FGs were, therefore, not conducted,
leaving a smaller than planned sample size for the participant FGs (13 participants recruited compared
with the planned number of 30–60 patients). Therefore, only tentative and relatively limited conclusions
can be drawn about women’s willingness to participate and the particular challenges of recruiting from
ethnic minority communities. We did, however, achieve our planned sample size for telephone interviews
with clinicians.
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Summary of results
Despite the curtailing of the participant FGs, the project has given rich information on the uncertainties
around modes of PTB controversies that any trial is most likely to be able to be address. It has also
identified potential challenges that will require careful thought in the design and conduct of any substantive
trial. The clinician survey demonstrated that there was most variation in practice for babies with a
breech presentation in spontaneous labour between 23 and 32 weeks’ gestation, and with indicated
PTB (e.g. for fetal growth restriction or pre-eclampsia) with a cephalic presentation of the baby. The parent
survey suggested that women and their families generally preferred vaginal birth at later gestations and CS
for preterm infants.
Regarding any potential trial, the interactive workshop and Delphi consensus process showed considerable
discrepancies in views around the appropriate participants to include. Different views were expressed on
the inclusion of, or exclusion of, women with a broad range of numbers of previous pregnancies, body mass
index, gestation of planned birth, presentation (breech or cephalic) and multiple pregnancy. In other words,
there was no strong feeling that any of these groups should be more focused or excluded. There was lower
enthusiasm for including women at very early gestations (e.g. prior to 24 weeks’ gestation) and moderately
lower enthusiasm for including women with a previous CS.
Other views that were strongly expressed at the consensus workshop were that women should be
spoken to early (i.e. prior to the onset of labour) about the study and that being inclusive (i.e. having
wide inclusion criteria) would be best.
Interviews with health-care professionals broadly supported the data provided in the health-care
professional survey. The need for more evidence (and, therefore, the case for a trial) was broadly
acknowledged. However, many interviewees anticipated that delivery of the proposed trial would
present considerable challenges. Interviewees highlighted the existence of strong MoB preferences
(i.e. lack of personal equipoise) and noted the potential of these to undermine support for the
proposed trial. Preferences were suggested as being most marked at the extremes of prematurity, in
breech presentations and in elective delivery scenarios (i.e. in the absence of labour). Preferences were
least marked at between 26 and 32 weeks’ gestation and with cephalic presentations and interviewees
surmised that they and/or their colleagues would find recruitment and randomisation less problematic
in these circumstances. Interviewees also conjectured that allowing individual hospitals or clinicians to
modify the inclusion/exclusion criteria within the range allowed by the protocol (in other words, not
to recruit particular groups of women, even though the protocol allowed it) might make the trial more
widely acceptable to health-care professionals. Some interviewees further suggested that confidence in
other aspects of the trial design, such as the utility and robustness of outcome measures, might need
attention for the trial to secure widespread support. Finally, interviewees highlighted several other
pragmatic issues that might make trial delivery challenging. These concerned the adequacy of local
service and research resources, as well as local clinical and research skills (e.g. trial expertise and
expertise in all study interventions, including vaginal breech birth).
Although data saturation was not achieved in the FGs, some issues emerged that suggest potentially
important concerns about trial participation. FG participants expressed unease about the potential for
randomisation to result in a woman having an unnecessary surgery. Participants found the idea of
being asked to make such ‘a big decision’ in the intrapartum period deeply problematic. As in the
consensus workshop, FG participants overwhelmingly favoured early provision of information prior to
the onset of labour. However, some participants also suggested that more personalised information
that is tailored to an individual’s particular circumstances, including their stage of pregnancy, should
be provided ahead of seeking consent. Additional issues relating to the provision of information and
securing of informed consent were identified as potentially important when English was not a woman’s
first language.
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Planning for a future trial
The CASSAVA project has overwhelmingly demonstrated that there is still a paucity of evidence and
lack of consistency in clinical opinion and practice on the optimal MoB for women having a baby
preterm, as well as an appetite among the health-care professional community for better evidence to
inform their practice. Although previous randomised trials have been attempted and have failed to recruit,3
a clinical trial is likely to be the only way to effectively address this uncertainty. In parallel with the
CASSAVA project, a formal update of a systematic review comparing methods of birth is being undertaken
(PROSPERO CRD42018097330) and completion of this systematic review is anticipated late in 2021.
However, it is not expected that this will address the fundamental uncertainty about the best MoB for
women with PTB.
Importantly, previous clinical trials in this area have failed to recruit sufficient participants to
determine optimal mode of delivery. CASSAVA has given some helpful indicators about how any trial
should be conducted. First, it is clear that potential participants (and clinicians) find the concept of
equipoise challenging and that early information for pregnant women on the uncertainties around the
best MoB for preterm babies and on the trial would be useful. Second, despite the lack of formal
evidence, not all clinicians and not all potential participants, are in equipoise about every clinical
situation. Reviewing the inclusion/exclusion criteria and/or allowing clinicians ‘not to recruit’ particular
patient groups, in the same way that individual participants are free to choose whether or not to
participate, would be important. Third, clinicians and participants would need to have confidence in the
trial design, in the resources for the trial and in the trial team to wish to participate. These resources
would include written and verbal translation for those whose preferred language is not English, updated
teaching in background information, in some methods of birth (e.g. vaginal breech birth) time to spend
discussing the trial with women well in advance of them being eligible for recruitment and a local
research team to address some of the local burden involved in participating in any trial. Particular issues
are likely to be experienced in including women from minority ethnic backgrounds. Various roadmaps56
and toolkits57 could provide useful information and an appropriately funded study within a trial58 might
be helpful in determining the most inclusive approach for involving pregnant women from ethnic
minorities at risk of PTB. Fourth, either a stand alone pilot/feasibility study (with relevant qualitative
work) or one nested within any substantive trial could inform trial procedures, and an adaptive design
might address the variety in participant characteristics. Last, although recruitment might be optimised
by restricting gestational age of entry and limiting the study setting to units with a co-tertiary neonatal
intensive care unit, it may also reduce generalisability.
Given the above issues, and the challenges created by COVID-19, the design and costing of a substantive
trial has not been finalised. The outline and detailed design of CASSAVAplus, which we used to consult
with potential participants and clinicians, provides a template that can be modified with feedback
gained and in the light of any information that emerges from a systematic review with regard to a likely
budget envelope.
The CASSAVA project has been crucial in defining what sort of trial could be conducted and how it
could best be performed. The CASSAVA project has also outlined the many, significant challenges in
conducting such a trial. The chairperson of our Study Steering Committee (Katie Morris) indicated that
a qualitative process evaluation nested within a National Institute for Health Research-funded trial,
C-STICH2 (Emergency Cervical Cerclage to Prevent Miscarriage and Preterm Birth – a Randomised
Controlled Trial; reference 16/151/01), identified similar themes to the CASSAVA qualitative research.
C-STICH2 has successfully recruited women to the RCT in this challenging area, but accrual is slow,
demonstrating the need for funders to appreciate the difficulties in these areas and demonstrating the
need for academics to consider novel methodology.
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Summary
We have demonstrated that a trial to determine the best MoB for women having a PTB would indeed
be challenging. However, we reject the suggestion that defining the optimal MoB for preterm babies is
‘too difficult’ for research. Around 60,000 (7%) babies are born preterm in the UK each year. MoB is
likely to influence the baby’s survival and health in infancy and in later life. Given the huge risks associated
with birth (which are not equalled until a person reaches the age of 92 years),59 to fail to define the optimal
MoB is unhelpful. The UK has a proud tradition of collaborative research in pregnancy health and we
believe that it is time that attention is turned to this most fundamental of questions for preterm babies –
what is the best MoB?
CONCLUSIONS
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Appendix 1 Updated search strategy and
outputs from relevant papers to inform the
Delphi survey
A search was conducted in MEDLINE using the medical subject headings premature birth ANDdelivery, obstetric AND randomised trial; premature birth AND caesarean delivery AND
randomised trial; premature birth AND labor; obstetric AND randomised trial, from January 2011.
MEDLINE
Date of search: 1 May 2019.
Date range searched: 1 January 1980 onwards.
Search strategy
1. (Preterm).ti,ab
2. (prematur* AND (neonat* OR neo-nat* OR infant OR baby OR babies)).ti,ab
3. exp “INFANT, PREMATURE”/
4. exp “PREMATURE BIRTH”/
5. OR/1-4
6. “mode of delivery”.ti
7. vaginal.ti
8. “trial of labor” OR “trial of labour”.ti
9. (cesarea* OR caesarea*).ti
10. (“c section*”).ti
11. (postcesarea* OR postcaesarea*).ti
12. exp *”CESAREAN SECTION”/
13. *”TRIAL OF LABOR”/
14. OR/6-13
15. (“randomized controlled trial”).pt
16. (“controlled clinical trial”).pt
17. (randomized OR randomly).ab






24. (case* ADJ5 control*).ti,ab
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36. 5 AND 14 AND 35
37. exp ANIMALS/NOT HUMANS/
38. 36 NOT 37
39. 38 [DT 2015-2017] [Languages English].
Additional scenarios
Additional scenario Relevant papers
Maternal factors
Body mass index Tetsuya et al., 2017; Houde et al., 2015; Khalak et al., 2015; Obican et al., 2015
Hypertensive disease Broekhuijsen et al., 2015; Feghali et al., 2015
Gestational diabetes Tetsuya et al., 2017; Mardy et al., 2016
Advancing maternal age Cui et al., 2016; Bereczky et al., 2015
PPROM Lorthe et al., 2017; Kim et al., 2017
Presence of cervical cerclage Story and Shannon, 2017
Chorioamnionitis Lorthe et al., 2017; Feghali et al., 2015
Maternal cardiac condition Hrycyk et al., 2016
Uterine abnormalities Cui et al., 2016
Other maternal medical condition Kim et al., 2017
Placental abnormalities Tetsuya et al., 2017; Racusin et al., 2016
Fetal factors
Gestational age Humberg et al., 2017; Thomas et al., 2016; Sentilhes et al., 2015; Holzer et al., 2017
Presentation: breech Thomas et al., 2016; Bergenhenegouwen et al., 2015; Kayem et al., 2015;
Lorthe et al., 2017
Presentation: cephalic Banister-Tyrrell et al., 2015
Worrying CTG Racusin et al., 2016
AGA/SGA/LGA Holzer et al., 2017; Racusin et al., 2016; Chen et al., 2016
Multiple pregnancies
Multiple pregnancies Hunter et al., 2017; Racusin et al., 2016; Spiegel et al., 2016; Sentilhes et al., 2015
Presentation of twins Hunter et al., 2017; Spiegel et al., 2016; Sentilhes et al., 2015
Maternal obstetric history
Previous vaginal delivery Plevani et al., 2016; Mardy et al., 2016; Watson et al., 2017
Previous PTB Wood et al, 2017; Mardy et al., 2016
Previous CS Plevani et al., 2016; Hrycyk et al., 2016; Spiegel et al., 2016; Tunc et al., 2016;
Rezavand et al., 2016; Mardy et al., 2016; Turitz et al., 2015
Previous CS during second stage Watson et al., 2017; Levine et al., 2015; Wood et al., 2017
Parity Lorthe et al., 2017; Kim et al., 2017; Bergenhenegouwen et al., 2015;
Feghali et al., 2015
AGA, appropriate for gestational age; CTG, cardiotocography; LGA, large for gestational age; PPROM, preterm
premature rupture of the membranes; SGA, small for gestation age.
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Appendix 2 Examples of comments from
the Delphi survey
• Parents might not be qualified enough to provide this type of feedback sought at this stage of the
study. I am not trained in quantitative methodologies or medical research, therefore, I feel unable to
provide a satisfactory answer at the moment.
• The preterm breach is a big problem – the indicated delivery group is too wide in the indication to
judge PET [pre-eclampsia] maybe different to just small baby.
• I feel randomised control trials are unethical in all the mentioned scenarios and observational studies
would be much more appropriate.
• I found it quite difficult to comment on the scenarios as a parent; rather than a trained professional.
I feel that I do not know enough about the risks involved in any of the given scenarios.
• It would be important to join up all scenarios into one or two that are as inclusive as possible.
• Preterm birth of < 24 weeks does not need to be included in the scenarios.
• Disclosure: although I have been invited to complete this as a parent; I am also a GP [general
practitioner] I found it difficult to commit to answers to the questions to randomisation of
delivery in breech presentation; due to safety concerns regarding delivery of these babies.
Does previous history of vaginal delivery need to be added so randomisation is stratified?
• Patients with prolonged ruptured membranes? For inclusion – not easy not know if vaginal birth
increases the risk; which may depend on the residual volume of amniotic fluid. Exclude uterine
anomalies and know pelvic malformations – I assume the trial will be for singletons only and not twins.
• It would be interesting to hear thoughts on all the presentations of breech – complete; incomplete and
frank and whether this changes management – Also women with two previous caesarean sections
presenting in preterm labour with a cephalic presentation – It would be good to focus more on
singleton pregnancies – so maybe multiple pregnancies as an exclusion.
• Lethal congenital anomalies.
• Exclusion: sepsis; CTG [cardiotocograph] abnormalities; uncertain diagnosis of labour to avoid
iatrogenic PTD [preterm delivery] in women with threatened preterm labour who would not have gone
on to deliver if in vaginal del arm.
• With the new BAPM [British Association of Perinatal Medicine]/RCOG/RCM [Royal College of
Midwives]/Bliss joint draft guidance now talking about resuscitation from 22 weeks – we do need to
talk about PTB and outcomes from previable gestation.
• I think it is reasonable to generalise some findings to other scenarios and therefore I am not too sure
of the necessity of informing practice with such individual cases.
• I think that the hardest decisions to make are those in spontaneous deliveries; they will also be the
hardest to recruit – but those are the patients I’d most like to see in the study!
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• I perform ultrasounds and cannot make any comment about other scenario.
• At less than 24 weeks I have said not critical as I would allow a vaginal delivery in these cases and do
not think that a CS should take place.
• Not sure how we are meant to know the answers to the questions for different weeks. I can only go
on the experience I have.
• Mothers who have been scanned continuously from 20 wks [weeks] are more likely to be more
anxious and feel less in control of the birthing plan. Trials on birthing method may help understand
which method of delivery would help both mother and child.
• No additional inclusion/exclusion criteria input at present – I continue to follow the progress of the
aforementioned study with interest.
• My experience in a clinical situation is not reflective of current practice in our trust but based on my
knowledge as a research midwife.
• 28–36 weeks is a very broad span in a potential indicated mode vaginal vs CS – If disease severity
enough to warrant delivery at 28 weeks (PE or FGR) [pre-eclampsia or fetal growth restriction] then
would be reluctant to wait for an induction. Where does parity come in? Decision-making in multip v
different to primip.
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Appendix 3 Summary hypothetical
trial protocol
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Screening: pregnant women
(n = 10,000) women ≥ 20+0 weeks’ and ≤ 36+6 weeks’ gestation
Consent: verbal or written
Women who fulf il the criteria
are ≥ 22+0 weeks’ and ≤ 36+6 weeks’ gestation and
delivery is likely to occur within the next 72 hours
Decline
Record on screening log
Written consent
(if not completed previously)
(n = 2400)
complete within 72 hours of delivery
Randomisation





at 6 months after birth
Exclusion
• Maternal or fetal indications 
    for CS
• Triplets or higher-order multiples
• Diagnosed intrauterine death
• Advanced labour
Inclusion
Women with a singleton or twin pregnancy with a cephalic,
f lexed breech or extended breech presentation and at risk of
a PTB because they have a history of:
OR have a planned preterm delivery
OR present with
• A preterm PROM
• Symptoms of preterm labour (def ined in protocol)
• Women for whom a decision has been made jointly by the clinician 
    and the woman for elective preterm delivery
• Elective preterm delivery is planned in the next 72 hours
• Previous PTB before 34 weeks’ gestation (spontaneous or induced)
• Cervical surgery (cone biopsy or cold coagulation)
• Short cervix or positive fFN in early pregnancy
FIGURE 17 Diagram of proposed CASSAVAplus trial. fFN, fetal fibronectin; PROM, premature rupture of membranes.
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Appendix 4 Full hypothetical trial protocol
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